

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2021

Commission File Number 001-38332



**QIAGEN N.V.  
Hulsterweg 82  
5912 PL Venlo  
The Netherlands**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**QIAGEN N.V.**  
**Form 6-K**  
**TABLE OF CONTENTS**

<b>Item</b>	<b>Page</b>
<a href="#">Other Information</a>	<a href="#">3</a>
<a href="#">Signatures</a>	<a href="#">4</a>
<a href="#">Exhibit Index</a>	<a href="#">5</a>

## **OTHER INFORMATION**

For the three and nine months ended September 30, 2021, QIAGEN N.V. prepared its quarterly report under United States generally accepted accounting principles (U.S. GAAP). This quarterly report is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

QIAGEN N.V.

BY:           /s/ Roland Sackers            
**Roland Sackers**  
**Chief Financial Officer**

Date: November 5, 2021

## EXHIBIT INDEX

Exhibit No.	Exhibit
----------------	---------

---

99.1	<a href="#">U.S. GAAP Quarterly Report for the Period Ended September 30, 2021</a>
------	--

## QIAGEN N.V. AND SUBSIDIARIES

## U.S. GAAP QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2021

## TABLE OF CONTENTS

## Financial Information

Condensed Consolidated Financial Statements	
<a href="#">Condensed Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020</a>	<a href="#">2</a>
<a href="#">Condensed Consolidated Statements of Income (unaudited) for the three and nine months ended September 30, 2021 and 2020</a>	<a href="#">4</a>
<a href="#">Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended September 30, 2021 and 2020</a>	<a href="#">6</a>
<a href="#">Condensed Consolidated Statements of Changes in Equity (unaudited) for the three and nine months ended September 30, 2021 and 2020</a>	<a href="#">7</a>
<a href="#">Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2021 and 2020</a>	<a href="#">9</a>
<a href="#">Notes to Condensed Consolidated Financial Statements (unaudited)</a>	<a href="#">10</a>
<a href="#">Operating and Financial Review and Prospects</a>	<a href="#">33</a>
<a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	<a href="#">41</a>
<a href="#">Recent Authoritative Pronouncements</a>	<a href="#">41</a>
<a href="#">Application of Critical Accounting Policies, Judgments and Estimates</a>	<a href="#">41</a>
<a href="#">Off-Balance Sheet Arrangements</a>	<a href="#">42</a>
<a href="#">Contractual Obligations</a>	<a href="#">42</a>
<a href="#">Legal Proceedings</a>	<a href="#">42</a>
<a href="#">Risk Factors</a>	<a href="#">42</a>

**QIAGEN N.V. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(in thousands)

	Note	September 30, 2021 (unaudited)	December 31, 2020
<b>Assets</b>			
<b>Current assets:</b>			
Cash and cash equivalents		\$ 617,541	\$ 597,984
Short-term investments		339,777	117,249
Accounts receivable, net of allowance for credit losses of \$26,156 and \$27,052 in 2021 and 2020, respectively		359,520	380,519
Inventories, net	(11)	335,691	291,181
Prepaid expenses and other current assets	(8)	375,867	237,472
<b>Total current assets</b>		<b>2,028,396</b>	1,624,405
<b>Long-term assets:</b>			
Property, plant and equipment, net of accumulated depreciation of \$633,706 and \$630,443 in 2021 and 2020, respectively		612,114	559,372
Goodwill	(6)	2,353,913	2,364,031
Intangible assets, net of accumulated amortization of \$776,342 and \$809,724 in 2021 and 2020, respectively	(6)	638,786	726,194
Deferred income tax assets		83,050	54,879
Fair value of derivative instruments	(8)	170,052	379,080
Other long-term assets	(5)	157,118	161,658
<b>Total long-term assets</b>		<b>4,015,033</b>	4,245,214
<b>Total assets</b>		<b>\$ 6,043,429</b>	<b>\$ 5,869,619</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**QIAGEN N.V. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(in thousands, except par value)

	Note	September 30, 2021 (unaudited)	December 31, 2020
<b>Liabilities and equity</b>			
<b>Current liabilities:</b>			
Current portion of long-term debt	(7)	\$ 371,637	\$ 42,539
Accounts payable		94,265	118,153
Accrued and other current liabilities	(8, 9, 13)	604,129	411,483
<b>Total current liabilities</b>		<b>1,070,031</b>	<b>572,175</b>
<b>Long-term liabilities:</b>			
Long-term debt, net of current portion	(7)	1,568,656	1,880,210
Fair value of derivative instruments	(8)	172,175	393,455
Other long-term liabilities	(9, 13)	196,725	186,724
Deferred income tax liabilities		22,102	39,216
<b>Total long-term liabilities</b>		<b>1,959,658</b>	<b>2,499,605</b>
<b>Commitments and contingencies</b>	(15)		
<b>Equity:</b>			
Preference shares, 0.01 EUR par value, authorized—450,000 shares, no shares issued and outstanding		—	—
Financing preference shares, 0.01 EUR par value, authorized—40,000 shares, no shares issued and outstanding		—	—
Common Shares, 0.01 EUR par value, authorized—410,000 shares, issued—230,829 shares in 2021 and 2020, respectively	(12)	2,702	2,702
Additional paid-in capital	(12)	1,811,538	1,834,169
Retained earnings		1,665,666	1,323,091
Accumulated other comprehensive loss	(12)	(291,601)	(243,822)
Less treasury shares, at cost—3,493 and 2,844 shares in 2021 and 2020, respectively	(12)	(174,565)	(118,301)
<b>Total equity</b>		<b>3,013,740</b>	<b>2,797,839</b>
<b>Total liabilities and equity</b>		<b>\$ 6,043,429</b>	<b>\$ 5,869,619</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.



**QIAGEN N.V. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**  
(in thousands, except per share data)

	Note	Three months ended September 30,	
		2021	2020
		(unaudited)	
Net sales	(13)	\$ 534,745	\$ 483,763
Cost of sales:			
Cost of sales		181,214	147,297
Acquisition-related intangible amortization		16,314	15,692
Total cost of sales		197,528	162,989
Gross profit		337,217	320,774
Operating expenses:			
Research and development		48,268	36,097
Sales and marketing		112,855	102,176
General and administrative		30,364	27,928
Acquisition-related intangible amortization		4,469	5,267
Restructuring, acquisition, integration and other, net	(4)	9,387	104,798
Total operating expenses		205,343	276,266
Income from operations		131,874	44,508
Other income (expense):			
Interest income		3,263	1,715
Interest expense		(14,576)	(18,052)
Other income (expense), net		30,894	(267)
Total other income (expense), net		19,581	(16,604)
Income before income taxes		151,455	27,904
Income tax expense		18,316	10,994
Net income		<u>\$ 133,139</u>	<u>\$ 16,910</u>
Basic earnings per common share		<u>\$ 0.58</u>	<u>\$ 0.07</u>
Diluted earnings per common share		<u>\$ 0.57</u>	<u>\$ 0.07</u>
Weighted-average shares outstanding			
Basic		228,060	228,733
Diluted		232,129	235,785

The accompanying notes are an integral part of these condensed consolidated financial statements.

**QIAGEN N.V. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**  
(in thousands, except share data)

	Note	Nine months ended September 30,	
		2021	2020
		(unaudited)	
Net sales	(13)	\$ 1,669,259	\$ 1,299,112
Cost of sales:			
Cost of sales		540,576	394,084
Acquisition-related intangible amortization		51,687	45,746
Total cost of sales		592,263	439,830
Gross profit		1,076,996	859,282
Operating expenses:			
Research and development		147,851	102,727
Sales and marketing		337,009	292,309
General and administrative		95,185	79,985
Acquisition-related intangible amortization		15,197	15,379
Restructuring, acquisition, integration and other, net	(4)	24,811	137,331
Long-lived asset impairments	(4)	—	1,034
Total operating expenses		620,053	628,765
Income from operations		456,943	230,517
Other income (expense):			
Interest income		6,974	8,396
Interest expense		(42,021)	(54,414)
Other income (expense), net		38,558	(1,514)
Total other income (expense), net		3,511	(47,532)
Income before income taxes		460,454	182,985
Income tax expense		77,041	36,482
Net income		\$ 383,413	\$ 146,503
Basic earnings per common share		\$ 1.68	\$ 0.64
Diluted earnings per common share		\$ 1.65	\$ 0.63
Weighted-average shares outstanding			
Basic		228,277	228,378
Diluted		232,125	234,008

The accompanying notes are an integral part of these condensed consolidated financial statements.

**QIAGEN N.V. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
(in thousands)

	Note	Three months ended September 30,	
		2021	2020
		(unaudited)	
Net income		<b>\$ 133,139</b>	\$ 16,910
Other comprehensive income (loss) to be reclassified to profit or loss in subsequent periods:			
Gains (losses) on cash flow hedges, net of tax of \$1.7 million in 2021 and \$2.6 million in 2020	(8)	4,952	(9,253)
Reclassification adjustments on cash flow hedges, net of tax of \$1.4 million in 2021 and \$2.0 million in 2020	(8)	(4,117)	7,187
Cash flow hedges, net of tax		835	(2,066)
Net investment hedge	(8)	6,720	(13,001)
Foreign currency translation adjustments, net of tax of \$0.1 million in 2021 and \$0.5 million in 2020		(38,190)	73,744
Total other comprehensive (loss) income		(30,635)	58,677
Comprehensive income		<b>\$ 102,504</b>	<b>\$ 75,587</b>

	Note	Nine months ended September 30,	
		2021	2020
		(unaudited)	
Net income		<b>\$ 383,413</b>	\$ 146,503
Other comprehensive income (loss) to be reclassified to profit or loss in subsequent periods:			
Gains on cash flow hedges, net of tax of \$3.3 million in 2021 and \$0.4 million in 2020	(8)	9,813	1,620
Reclassification adjustments on cash flow hedges, net of tax of \$3.1 million in 2021 and \$1.9 million in 2020	(8)	(9,342)	6,680
Cash flow hedges, net of tax		471	8,300
Net investment hedge	(8)	19,164	(12,084)
Foreign currency translation adjustments, net of tax of \$0.6 million in 2021 and \$1.1 million in 2020		(67,414)	20,469
Total other comprehensive (loss) income		(47,779)	16,685
Comprehensive income		<b>\$ 335,634</b>	<b>\$ 163,188</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(in thousands)

(unaudited)	Note	Common Shares		Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Shares		Total Equity
		Shares	Amount				Shares	Amount	
Balance at June 30, 2021		230,829	\$ 2,702	\$ 1,799,414	\$ 1,537,485	\$ (260,966)	(2,191)	\$(100,763)	\$ 2,977,872
Net income		—	—	—	133,139	—	—	—	133,139
Unrealized gain, net on hedging contracts	(8)	—	—	—	—	11,672	—	—	11,672
Realized gain, net on hedging contracts	(8)	—	—	—	—	(4,117)	—	—	(4,117)
Translation adjustment, net	(12)	—	—	—	—	(38,190)	—	—	(38,190)
Purchase of treasury shares	(12)	—	—	—	—	—	(1,580)	(83,838)	(83,838)
Issuance of common shares in connection with stock plan		—	—	—	(4,958)	—	279	10,109	5,151
Tax withholding related to vesting of stock awards	(16)	—	—	—	—	—	(1)	(73)	(73)
Share-based compensation	(16)	—	—	12,124	—	—	—	—	12,124
<b>Balance at September 30, 2021</b>		<b>230,829</b>	<b>\$ 2,702</b>	<b>\$ 1,811,538</b>	<b>\$ 1,665,666</b>	<b>\$ (291,601)</b>	<b>(3,493)</b>	<b>\$(174,565)</b>	<b>\$ 3,013,740</b>
Balance at June 30, 2020		230,829	\$ 2,702	\$ 1,793,521	\$ 1,262,077	\$ (351,611)	(2,343)	\$ (85,838)	\$ 2,620,851
Net income		—	—	—	16,910	—	—	—	16,910
Conversion of warrants	(12)	—	—	(2,963)	—	—	252	—	(2,963)
Unrealized loss, net on hedging contracts	(8)	—	—	—	—	(22,254)	—	—	(22,254)
Realized loss, net on hedging contracts	(8)	—	—	—	—	7,187	—	—	7,187
Translation adjustment, net	(12)	—	—	—	—	73,744	—	—	73,744
Issuance of common shares in connection with stock plan		—	—	—	(7,023)	—	13	10,085	3,062
Tax withholding related to vesting of stock awards	(16)	—	—	—	—	—	(2)	(121)	(121)
Share-based compensation	(16)	—	—	14,717	—	—	—	—	14,717
<b>Balance at September 30, 2020</b>		<b>230,829</b>	<b>\$ 2,702</b>	<b>\$ 1,805,275</b>	<b>\$ 1,271,964</b>	<b>\$ (292,934)</b>	<b>(2,080)</b>	<b>\$(75,874)</b>	<b>\$ 2,711,133</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(in thousands)

(unaudited)	Note	Common Shares		Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Shares		Total Equity
		Shares	Amount				Shares	Amount	
Balance at December 31, 2020		230,829	\$ 2,702	\$ 1,834,169	\$ 1,323,091	\$ (243,822)	(2,844)	\$(118,301)	\$ 2,797,839
ASU 2020-06 impact of change in accounting policy	(2)	—	—	(54,052)	263	—	—	—	(53,789)
Net income		—	—	—	383,413	—	—	—	383,413
Unrealized gain, net on hedging contracts	(8)	—	—	—	—	28,977	—	—	28,977
Realized gain, net on hedging contracts	(8)	—	—	—	—	(9,342)	—	—	(9,342)
Purchase of treasury shares	(12)	—	—	—	—	—	(1,580)	(83,838)	(83,838)
Translation adjustment, net	(12)	—	—	—	—	(67,414)	—	—	(67,414)
Issuance of common shares in connection with stock plan		—	—	—	(41,101)	—	1,353	48,966	7,865
Tax withholding related to vesting of stock awards	(16)	—	—	—	—	—	(422)	(21,392)	(21,392)
Share-based compensation	(16)	—	—	31,421	—	—	—	—	31,421
<b>Balance at September 30, 2021</b>		<b>230,829</b>	<b>\$ 2,702</b>	<b>\$ 1,811,538</b>	<b>\$ 1,665,666</b>	<b>\$ (291,601)</b>	<b>(3,493)</b>	<b>\$(174,565)</b>	<b>\$ 3,013,740</b>
Balance at December 31, 2019		230,829	\$ 2,702	\$ 1,777,017	\$ 1,178,457	\$ (309,619)	(3,077)	\$(111,966)	\$ 2,536,591
ASC 326 impact of change in accounting policy		—	—	—	(15,074)	—	—	—	(15,074)
Net income		—	—	—	146,503	—	—	—	146,503
Conversion of warrants	(12)	—	—	(2,963)	—	—	252	—	(2,963)
Unrealized loss, net on hedging contracts	(8)	—	—	—	—	(10,464)	—	—	(10,464)
Realized loss, net on hedging contracts	(8)	—	—	—	—	6,680	—	—	6,680
Translation adjustment, net	(12)	—	—	—	—	20,469	—	—	20,469
Issuance of common shares in connection with stock plan		—	—	—	(37,922)	—	1,049	48,365	10,443
Tax withholding related to vesting of stock awards	(16)	—	—	—	—	—	(304)	(12,273)	(12,273)
Share-based compensation	(16)	—	—	31,221	—	—	—	—	31,221
<b>Balance at September 30, 2020</b>		<b>230,829</b>	<b>\$ 2,702</b>	<b>\$ 1,805,275</b>	<b>\$ 1,271,964</b>	<b>\$ (292,934)</b>	<b>(2,080)</b>	<b>\$( 75,874)</b>	<b>\$ 2,711,133</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**QIAGEN N.V. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(in thousands)

	Note	Nine months ended September 30,	
		2021	2020
<b>(unaudited)</b>			
Cash flows from operating activities:			
Net income		\$ 383,413	\$ 146,503
Adjustments to reconcile net income to net cash provided by operating activities, net of effects of businesses acquired:			
Depreciation and amortization		163,830	147,844
Non-cash impairments	(4)	—	1,034
Amortization of debt discount and issuance costs	(7)	24,095	31,379
Share-based compensation expense	(16)	31,421	31,221
Deferred income tax benefit		(29,394)	(17,793)
Loss (gain) on marketable securities	(5)	2,816	(1,343)
(Gain) loss on sale of investment	(5)	(36,086)	1,467
Other items, net including fair value changes in derivatives		13,005	(1,566)
Net changes in operating assets and liabilities:			
Accounts receivable		5,139	(9,016)
Inventories		(75,613)	(77,777)
Prepaid expenses and other current assets		(5,582)	(40,222)
Other long-term assets		1,310	(82)
Accounts payable		(13,676)	(7,496)
Accrued and other current liabilities		(52,385)	(47,682)
Income taxes		3,520	1,768
Other long-term liabilities		24,730	29,855
Net cash provided by operating activities		<u>440,543</u>	<u>188,094</u>
Cash flows from investing activities:			
Purchases of property, plant and equipment		(138,166)	(86,746)
Purchases of intangible assets	(6)	(14,365)	(150,851)
(Purchases of) proceeds from investments, net	(5)	(2,199)	1,001
Cash paid for acquisitions, net of cash acquired	(3)	—	(239,572)
Purchases of short-term investments		(362,683)	(49,770)
Proceeds from sales of short-term investments	(5)	172,223	144,621
Cash received (paid) for collateral asset	(8)	47,430	(4,317)
Other investing activities		43	(3,145)
Net cash used in investing activities		<u>(297,717)</u>	<u>(388,779)</u>
Cash flows from financing activities:			
Repayment of long-term debt	(7)	(41,345)	(23,200)
Proceeds from issuance of common shares		7,865	7,479
Tax withholding related to vesting of stock awards	(16)	(21,392)	(13,422)
Purchase of treasury shares	(12)	(82,292)	—
Cash received for collateral liability	(8)	19,600	15,100
Other financing activities		(1,833)	(3,551)
Proceeds from short-term debt		—	59,345
Proceeds from exercise of call option related to cash convertible notes		—	12,271
Payment of intrinsic value of cash convertible notes		—	(11,233)
Net cash (used in) provided by financing activities		<u>(119,397)</u>	<u>42,789</u>
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(3,872)	(2,203)
Net increase (decrease) in cash, cash equivalents and restricted cash		19,557	(160,099)
Cash, cash equivalents and restricted cash, beginning of period		597,984	629,390
Cash, cash equivalents and restricted cash, end of period		<u>\$ 617,541</u>	<u>\$ 469,291</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**QIAGEN N.V. AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(unaudited)**

**1. CORPORATE INFORMATION**

---

***Corporate Information***

QIAGEN N.V. is a public limited liability company ('naamloze vennootschap') under Dutch law with registered office at Hulsterweg 82, 5912 PL Venlo, The Netherlands. QIAGEN N.V., a Netherlands holding company, and subsidiaries (we, our or the Company) is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. We provide solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2021, we had more than 6,000 employees in over 35 locations worldwide.

**2. BASIS OF PRESENTATION AND ACCOUNTING POLICIES**

---

***Basis of Presentation***

The condensed consolidated financial statements include the accounts of QIAGEN N.V. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. All amounts are presented in U.S. dollars, unless otherwise indicated. Investments in either common stock or in-substance common stock of companies where we exercise significant influence over the operations but do not have control, and where we are not the primary beneficiary, are accounted for using the equity method. All other investments are accounted for at our initial cost, minus any impairment, plus or minus changes from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and generally in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the Securities and Exchange Commission (SEC) rules and regulations. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary for a fair presentation have been included.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. While the changing conditions around the COVID-19 pandemic present additional uncertainty, we continue to use the best information available to form our estimates. Actual results could differ from those estimates.

We undertake business combinations to complement our own internal product development activities. In 2020, we completed the acquisition of the remaining shares of NeuMoDx Molecular, Inc. ("NeuMoDx"), a privately-held U.S. company that designs and develops molecular diagnostics solutions for hospital and clinical reference laboratories. Accordingly, at the acquisition date, all the assets acquired and liabilities assumed were recorded at their respective fair values and our consolidated results of operations include the operating results from the acquired company from the acquisition date.

We operate as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, *Segment Reporting*. We have a common basis of organization and our products and services are offered globally. Our chief operating decision maker (CODM) makes decisions based on the Company as a whole. Accordingly, we operate and make decisions as one reporting unit.

The results of operations for an interim period are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in

conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 20-F for the year ended December 31, 2020. Certain reclassifications to prior year balances have been made to conform to the current year presentation.

### **Summary of Significant Accounting Policies**

The interim condensed consolidated financial statements were prepared based on the same accounting policies as those applied and described in the consolidated financial statements as of December 31, 2020, other than as described below for the adoption of new accounting standards as of January 1, 2021.

### **Adoption of New Accounting Standards**

The following new FASB Accounting Standards Updates (ASU) were adopted in 2021:

ASU 2019-12, *Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes*, removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod tax allocations and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating income taxes to members of a consolidated group. ASU 2019-12 is effective for annual periods beginning on January 1, 2021, with earlier adoption permitted. We adopted the ASU on the effective date of January 1, 2021 and the adoption of this guidance did not have an impact on our consolidated financial statements on the date of adoption. Ultimately, the impact in future periods will be dependent on the extent to which events or conditions would be affected such as enacted changes in tax laws or rates.

ASU 2020-06, *Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity*, reduces the number of accounting models for convertible instruments. The ASU also amends diluted earnings per share (EPS) calculations for convertible instruments, which will result in more dilutive EPS results. The ASU also amends the requirements for a contract (or embedded derivative) that is potentially settled in an entity's own shares to be classified in equity. ASU 2020-06 is effective for annual periods beginning on January 1, 2022, with earlier adoption on January 1, 2021 permitted. We adopted ASU 2020-06 early on January 1, 2021 and this resulted in a decrease of \$54.1 million to additional paid in capital and an increase of \$0.3 million to retained earnings for the conversion feature to the liability for our 2027 Convertible Notes further discussed in Note 7 "Debt".

### **New Accounting Standards Not Yet Adopted**

The following new FASB Accounting Standards Updates, which are not yet adopted, have effective dates through December 31, 2022:

ASU 2020-04, *Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting*, provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. Companies can apply the ASU immediately. However, the guidance will only be available for a limited time, generally through December 31, 2022. We are evaluating the potential impact that ASU 2020-04 may have on our consolidated financial statements.

ASU 2021-04, *Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options*, clarifies and reduces diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments affect all entities that issue freestanding written call options that are classified in equity. Specifically, the amendments affect those entities when a freestanding equity-classified written call option is modified or exchanged and remains equity classified after the modification or exchange. The amendments that relate to the recognition and measurement of EPS for certain modifications or exchanges of freestanding equity-classified written call options affect entities that present EPS in accordance with the guidance in Topic 260, Earnings Per Share. The amendments are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. We are evaluating the potential impact that ASU 2021-04 may have on our consolidated financial statements.



### 3. ACQUISITIONS

---

#### ***Business Combinations and Asset Acquisitions***

For acquisitions which have been accounted for as business combinations, the acquired companies' results have been included in the accompanying condensed consolidated statements of income from their respective dates of acquisition. Our acquisitions have historically been made at prices above the fair value of the acquired net assets, resulting in goodwill, due to expectations of synergies of combining the businesses. These synergies include use of our existing infrastructure, such as sales force, shared service centers, distribution channels and customer relations, to expand sales of an acquired business' products; use of the infrastructure of the acquired businesses to cost-effectively expand sales of our products; and elimination of duplicative facilities, functions and staffing.

If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired in-process research and development with no alternative future use is charged to expense at the acquisition date.

#### *2020 Business Combination*

In September 2020, we completed the acquisition of the remaining 80.1% of shares of NeuMoDx Molecular, Inc. ("NeuMoDx"), a privately-held U.S. company in which we held a minority interest. NeuMoDx designs and develops molecular diagnostics solutions for hospital and clinical reference laboratories. Prior to acquisition, we held a 19.9% investment in NeuMoDx with a carrying value of \$41.0 million. The cash consideration for the remaining shares totaled \$251.7 million. We incurred \$2.5 million acquisition related costs to effect the business combination, of which \$0.5 million and \$0.8 million, respectively, were incurred during the three and nine months ended September 30, 2020 and are included in restructuring, acquisition, integration and other, net.

The acquisition date fair value of the minority interest investment was \$52.7 million and a gain of \$11.7 million was recorded in restructuring, acquisition, integration and other, net in the consolidated statement of income for the period ending September 30, 2020. The fair value of the minority interest investment was determined using an implied purchase price reduced by a 20% control premium.

The final purchase price allocation differed from the preliminary purchase price allocation primarily as a result of updates to the acquisition date value of the liability related to acquired litigation, the final valuation and allocation of amounts among the acquired intangible assets as set forth in an independent appraisal, and related deferred tax impacts as follows:

(in thousands)	Final	Preliminary as of September 30, 2020	Difference
<b>Purchase Price:</b>			
Cash consideration	\$ 251,730	\$ 251,730	\$ —
Fair value of minority interest	52,727	52,727	—
	<b>\$ 304,457</b>	<b>\$ 304,457</b>	<b>\$ —</b>
<b>Preliminary Allocation:</b>			
Cash and cash equivalents	\$ 12,291	\$ 12,291	\$ —
Accounts receivable	5,691	5,691	—
Inventories	20,271	18,866	1,405
Prepaid expenses and other current assets	5,961	5,943	18
Accounts payable	(12,450)	(11,168)	(1,282)
Accruals and other current liabilities	(69,585)	(18,770)	(50,815)
Other long-term liabilities	(4,101)	(4,101)	—
Fixed and other long-term assets	7,076	6,698	378
Developed technology	101,000	119,100	(18,100)
In-process research and development	55,000	64,800	(9,800)
Patents and license rights	770	770	—
Customer backlog	400	900	(500)
Goodwill	191,343	149,877	41,466
Deferred tax asset	30,057	—	30,057
Deferred tax liability on fair value of identifiable intangible assets acquired	(39,267)	(46,440)	7,173
<b>Total</b>	<b>\$ 304,457</b>	<b>\$ 304,457</b>	<b>\$ —</b>

The final purchase price allocation includes \$55.0 million for the acquisition date value of the liability related to acquired litigation. As of September 30, 2021, current accrued liabilities include \$53.0 million for this matter. The \$2.0 million adjustment to the liability was recorded to restructuring, acquisition, integration and other expense, net in the three months ended September 30, 2021. The in-process research and development relates to technologies that remain in development and have not yet obtained regulatory approvals. The technologies within in-process research and development are expected to be completed within the next four years. The weighted average amortization period for the acquired intangibles is 10 years. The goodwill acquired is not deductible for tax purposes.

#### ***Pro forma results***

The following unaudited pro forma information assumes that the above acquisition occurred at the beginning of the periods presented. For the three-month period ended September 30, 2020, pro forma net sales would have been \$496.0 million and pro forma net income would have been \$0.1 million resulting in no pro forma diluted net income per common share. For the nine-month period ended September 30, 2020, pro forma net sales would have been \$1.33 billion, pro forma net income would have been \$122.6 million and pro forma diluted net income per common share would have been \$0.52. These unaudited pro forma results are intended for informational purposes only and are not necessarily indicative of the results of operations that would have occurred had the acquisition been in effect at the beginning of the periods presented, or of future results of the combined operations.

#### **4. RESTRUCTURING AND IMPAIRMENTS**

As part of our restructuring activities, we incur expenses that qualify as exit and disposal costs under U.S. GAAP including severance and employee costs as well as contract and other costs, primarily contract termination costs, as well as inventory write-offs and other implementation costs primarily related to consulting fees. Personnel related costs primarily relate to cash severance and other termination benefits including accelerated share-based compensation. We also incur expenses that are an integral component of, and are directly attributable to, our restructuring activities which do not qualify

as exit and disposal costs under U.S. GAAP, which consist of asset-related costs such as intangible asset impairments and other asset related write-offs.

Personnel costs are primarily determined based on established benefit arrangements, local statutory requirements, or historical benefit practices. We recognize these benefits when payment is probable and estimable. Other benefits which require future service and are associated to non-recurring benefits are recognized ratably over the future service period. Other assets, including inventory, are impaired or written-off if the carrying value exceeds the fair value. All other costs are recognized as incurred.

### 2019 Restructuring

In the second half of 2019, we decided to suspend development of NGS-related instrument systems and entered into a new strategic partnership with Illumina to commercialize IVD kits worldwide on Illumina's diagnostic sequencers. In order to align our business with this new strategy, we began restructuring initiatives to target resource allocation to growth opportunities in our Sample to Insight portfolio.

During 2020, certain of the planned measures were delayed during the acquisition attempt by Thermo Fisher or changed as a result of business needs during the pandemic. The following is a summary of the charges related to the 2019 restructuring program recorded in the condensed consolidated statements of income during the nine months ended September 30, 2021 and cumulatively through September 30, 2021.

Classification and Type of Charge (in thousands)	Nine months ended September 30, 2021	Total program charges through September 30, 2021
Restructuring, acquisition, integration and other, net		
Personnel related	\$ 940	\$ 72,422
Contract and other costs	2,058	56,142
Accounts receivable	(246)	9,957
Inventories	—	13,350
Prepaid expenses and other current assets	—	17,139
	<u>2,752</u>	<u>169,010</u>
Long-lived asset impairments		
Property, plant and equipment	—	99,506
Intangible assets	—	40,301
	<u>—</u>	<u>139,807</u>
Other expense, net		
Equity method investment impairment	—	4,799
	<u>—</u>	<u>4,799</u>
Total	<u>\$ 2,752</u>	<u>\$ 313,616</u>

Of the total costs incurred, \$3.9 million and \$11.2 million were accrued as of September 30, 2021 and December 31, 2020, respectively, in accrued and other current liabilities in the accompanying condensed consolidated balance sheets as summarized in the following table that includes the cash components of the restructuring activity.

(in thousands)	Personnel Related	Contract and Other Costs	Total
Liability at December 31, 2020	\$ 4,687	\$ 6,479	\$ 11,166
Additional costs incurred in 2021	1,681	7,330	9,011
Release of accrual	(741)	(5,272)	(6,013)
Payments	(4,818)	(5,161)	(9,979)
Foreign currency translation adjustment	(143)	(179)	(322)
Liability at September 30, 2021	<u>\$ 666</u>	<u>\$ 3,197</u>	<u>\$ 3,863</u>

Future pre-tax costs up to \$1 million are expected to be incurred primarily related to personnel and consulting in the remainder of 2021.

## 5. INVESTMENTS

The following discusses our non-marketable investments, marketable investments, and the realized and unrealized gains and losses on these investments.

### **Non-Marketable Investments**

We have made strategic investments in certain privately-held companies without readily determinable market values.

#### *Non-Marketable Investments Accounted for Under the Equity Method*

As of September 30, 2021, we had total non-marketable investments that were accounted for as equity method investments of \$15.4 million, of which \$15.8 million is included in other long-term assets and \$0.4 million, where we are committed to fund losses, is included in other long-term liabilities in the accompanying condensed consolidated balance sheet. As of December 31, 2020, these investments totaled \$11.0 million, of which \$11.5 million is included in other long-term assets and \$0.5 million is included in other long-term liabilities.

During the nine months ended September 30, 2021, we made additional investments of \$3.0 million in non-marketable investments accounted for under the equity method. Additionally, we sold a portion of an investment with a carrying value of \$0.6 million in exchange for cash of \$0.9 million. A corresponding gain of \$0.3 million was recognized in other income, net on this sale in the accompanying condensed consolidated statements of income for the three- and nine-month periods ended September 30, 2021.

Three of our equity method investments are variable interest entities and we are not considered the primary beneficiary as we do not hold the power to direct the activities that most significantly impact the economic performance of these entities and therefore, these investments are not consolidated. As of September 30, 2021, these investments had a total carrying value which totaled \$6.0 million, of which \$6.4 million, representing our maximum exposure to loss, is included in other long-term assets and \$0.4 million is included in other long-term liabilities in the accompanying condensed consolidated balance sheet. As of December 31, 2020, these investments totaled \$3.0 million, of which \$3.5 million is included on other long-term assets and \$0.5 million is included in other long-term liabilities.

#### *Non-Marketable Investments Not Accounted for Under the Equity Method*

At September 30, 2021 and December 31, 2020, we had investments in non-publicly traded companies that do not have readily determinable fair values with carrying amounts that totaled \$4.1 million which are included in other long-term assets in the accompanying condensed consolidated balance sheets. These investments are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Changes resulting from impairment and observable price changes are recognized in the statements of income during the period the change is identified.

The changes in non-marketable investments not accounted for under the equity method during the nine months ended September 30, 2021 and 2020 are as follows:

(in thousands)	2021	2020
Balance at beginning of year	\$ 4,142	\$ 70,849
Cash investments in equity securities, net	110	106
Sale of equity securities	—	(250)
Loss on sale of equity securities	—	(2,250)
Full acquisition of equity securities	—	(41,001)
Foreign currency translation adjustments	(202)	282
Balance at end of period	<u>\$ 4,050</u>	<u>\$ 27,736</u>

We made additional investments of \$0.1 million in non-marketable investments not accounted for under the equity method during the nine months ended September 30, 2021.

In the above table, the nine months ended September 30, 2020 includes the value of our investment in ArcherDX which we sold to Invitae in October 2020. During the third quarter of 2020, we acquired the remaining shares of NeuMoDx as further discussed in Note 3 "Acquisitions". We held a 19.9% investment in NeuMoDx with a book value of \$41.0 million prior to the acquisition. During the first quarter of 2020, we sold an investment in equity securities with a carrying amount of \$2.5 million in exchange for \$0.3 million including the shares in OncoCyte, as discussed above. A corresponding loss of \$2.3 million was recognized in other income (expense), net in the accompanying condensed consolidated statement of income for the nine months ended September 30, 2020. Also, we made additional investments of \$0.1 million in non-marketable investments not accounted for under the equity method during the nine months ended September 30, 2020.

## Marketable Investments

As of December 30, 2020, we held investments in marketable equity securities with readily determinable fair values. These investments were reported at fair value with gains and losses recorded in earnings. These marketable investments were all sold in 2021.

The changes in marketable equity securities during the nine months ended September 30, 2021 are as follows:

(in \$ thousands, except shares data)	Invitae Corporation (Invitae)		OncoCyte Corporation (OncoCyte)		Oncimmune Holdings plc (Oncimmune)		HTG Molecular Diagnostics, Inc (HTGM)	
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount
Balance at December 31, 2020	2,769,189	\$ 115,780	88,101	\$ 211	560,416	\$ 1,258	55,556	\$ 266
Shares received upon milestone achievement	<b>1,100,190</b>	<b>35,338</b>	<b>30,152</b>	<b>147</b>	<b>86,218</b>	<b>220</b>	—	—
(Loss) gain on change in fair value	—	<b>(3,066)</b>	—	<b>123</b>	—	<b>61</b>	—	<b>65</b>
Sale of investment	<b>(3,869,379)</b>	<b>(148,052)</b>	<b>(118,253)</b>	<b>(481)</b>	<b>(646,634)</b>	<b>(1,539)</b>	<b>(55,556)</b>	<b>(331)</b>
Balance at September 30, 2021	<u>—</u>	<u>\$ —</u>	<u>—</u>	<u>\$ —</u>	<u>—</u>	<u>\$ —</u>	<u>—</u>	<u>\$ —</u>

We are entitled to up to 0.6 million Invitae shares and up to approximately \$3.0 million from OncoCyte in the future upon achievement of certain milestones.

As of December 31, 2020, we held marketable equity securities included in short-term investment and other long-term assets in the accompanying condensed consolidated balance sheet as follows:

(in thousands, except shares held)	Short-Term			Long-Term
	Invitae	OncoCyte	Oncimmune	HTGM
Shares held	2,769,189	88,101	560,416	55,556
Cost basis	\$ 100,822	\$ 230	\$ 657	\$ 2,000
Fair value	\$ 115,780	\$ 211	\$ 1,258	\$ 266
Total cumulative unrealized gain (loss)	\$ 14,958	\$ (19)	\$ 601	\$ (1,734)

In 2020, HTGM completed a 15:1 reverse stock split.

In the first quarter of 2020, as part of consideration received upon the sale of a non-marketable investment not accounted for under the equity method, we received 88,101 shares in OncoCyte. On the date of receipt, these shares had a fair value of \$0.2 million.

During the three and nine months ended September 30, 2020, losses of \$0.2 million and gains of \$0.3 million, respectively, for the change in fair market value of all marketable equity securities were recognized in other income (expense), net in the accompanying condensed consolidated statements of income.

## 6. INTANGIBLE ASSETS

The following sets forth the intangible assets by major asset class as of September 30, 2021 and December 31, 2020:

(in thousands)	September 30, 2021		December 31, 2020	
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization
<b>Amortized Intangible Assets:</b>				
Patent and license rights	\$ 287,457	\$ (201,546)	\$ 298,395	\$ (197,038)
Developed technology	799,568	(372,403)	860,129	(378,705)
Customer base, non-compete agreements and trademarks	266,009	(202,393)	314,876	(233,981)
	<u>\$ 1,353,034</u>	<u>\$ (776,342)</u>	<u>\$ 1,473,400</u>	<u>\$ (809,724)</u>
<b>Unamortized Intangible Assets:</b>				
In-process research and development	\$ 62,094		\$ 62,518	
Goodwill	2,353,913		2,364,031	
	<u>\$ 2,416,007</u>		<u>\$ 2,426,549</u>	

The in-process research and development as of September 30, 2021 is from the acquisitions of NeuMoDx in 2020 and STAT-Dx in 2018. The estimated fair value of acquired in-process research and development projects which have not reached technological feasibility at the date of acquisition are capitalized and subsequently tested for impairment through completion of the development process, at which point the capitalized amounts are amortized over their estimated useful life. If a project is abandoned rather than completed, all capitalized amounts are written-off immediately.

The changes in intangible assets in 2021 are summarized as follows:

(in thousands)	Intangibles	Goodwill
Balance at December 31, 2020	\$ 726,194	\$ 2,364,031
Purchase adjustments	—	33,716
Additions	8,917	—
Amortization	(81,057)	—
Disposals	(4,571)	—
Foreign currency translation adjustments	(10,697)	(43,834)
<b>Balance at September 30, 2021</b>	<u>\$ 638,786</u>	<u>\$ 2,353,913</u>

Cash paid for purchases of intangible assets during the nine months ended September 30, 2021 totaled \$14.4 million, of which \$6.3 million is related to current year payments for assets that were accrued as of December 31, 2020 and \$0.1 million is related to prepayments recorded in other long-term assets in the accompanying condensed consolidated balance sheet. Intangible additions of \$8.9 million includes \$8.0 million of cash paid during the year and \$0.9 million of additions which were previously recorded as prepayments.

The decrease in the carrying amount of goodwill for the nine months ended September 30, 2021 resulted from changes in foreign currency translation partially offset by purchase adjustments.

For the three- and nine-month periods ended September 30, 2021 and 2020, amortization expense on intangible assets totaled approximately \$25.5 million and \$81.1 million, and \$27.5 million and \$75.9 million, respectively. Amortization of intangibles for the next five years is expected to be approximately:

Year	Annual Amortization (in millions)
2022	\$ 90.4
2023	\$ 87.9
2024	\$ 84.2
2025	\$ 72.3
2026	\$ 64.2

## 7. DEBT

At September 30, 2021 and December 31, 2020, total current long-term debt, net of debt issuance costs consists of the following:

(in thousands)	September 30, 2021	December 31, 2020
0.875% Senior Unsecured Cash Convertible Notes due 2021	\$ —	\$ 200
0.500% Senior Unsecured Cash Convertible Notes due 2023	371,637	361,304
1.000% Senior Unsecured Cash Convertible Notes due 2024	442,176	429,496
0.000% Senior Unsecured Convertible Notes due 2027	496,670	442,481
3.75% Series B Senior Notes due October 16, 2022	302,793	304,761
3.90% Series C Senior Notes due October 16, 2024	26,965	26,956
German Private Placement (Schuldschein)	300,052	357,551
Total long-term debt	<u>\$ 1,940,293</u>	<u>\$ 1,922,749</u>
Less: current portion	<u>371,637</u>	<u>42,539</u>
Long-term portion	<u>\$ 1,568,656</u>	<u>\$ 1,880,210</u>

In the first nine months of 2021, we repaid \$41.1 million for two tranches of the German Private Placement bond (Schuldschein) that matured and the remaining \$0.2 million of 2021 Notes was repaid at the original maturity on March 19, 2021.

The notes are all unsecured obligations that rank pari passu.

The principal amount, carrying amount and fair values of long-term debt instruments are summarized below:

(in thousands)	As of September 30, 2021				
	Principal Amount	Unamortized debt discount and issuance costs	Carrying Amount	Fair Value	
				Amount	Leveling
Cash Convertible Notes due 2023	\$ 400,000	\$ (28,363)	\$ 371,637	\$ 519,656	Level 1
Cash Convertible Notes due 2024	500,000	(57,824)	442,176	620,300	Level 1
Convertible Notes due 2027	500,000	(3,330)	496,670	507,610	Level 1
U.S. Private Placement <sup>(1)</sup>	329,960	(202)	329,758	333,446	Level 2
German Private Placement	300,317	(265)	300,052	302,862	Level 2
	<u>\$ 2,030,277</u>	<u>\$ (89,984)</u>	<u>\$ 1,940,293</u>	<u>\$ 2,283,874</u>	

<sup>(1)</sup> The principal amount of the U.S Private Placement includes the \$3.0 million impact of the interest rate swaps which qualify for hedge accounting as fair value hedges which are further discussed in Note 8 "Derivatives and Hedging".

Interest expense related to the convertible notes for the three and nine months ended September 30, 2021 and 2020 was comprised of the following:

(in thousands)	Three months ended		Nine months ended	
	September 30,		September 30,	
	2021	2020	2021	2020
Coupon interest	\$ 1,750	\$ 2,277	\$ 5,250	\$ 7,018
Amortization of original issuance discount	7,255	10,269	21,528	28,591
Amortization of debt issuance costs	632	801	1,884	2,208
Total interest expense related to the convertible notes	<u>\$ 9,637</u>	<u>\$ 13,347</u>	<u>\$ 28,662</u>	<u>\$ 37,817</u>

### Convertible Notes due 2027

On December 17, 2020, we issued zero coupon convertible notes in an aggregate principal amount of \$500.0 million with a maturity date of December 17, 2027 (2027 Notes). The 2027 Notes carry no coupon interest. The net proceeds of the 2027 Notes totaled \$497.6 million, after debt issuance costs of \$3.7 million, of which \$0.1 million was accrued as of September 30, 2021. The debt issuance costs are amortized to interest expense over the term of the 2027 Notes.

In accounting for the issuance of the 2027 Notes in 2020 prior to the adoption of ASU 2020-06, we separated the 2027 Notes into liability and equity components. We allocated \$445.9 million of the 2027 Notes to the liability component, representing the fair value of a similar debt instrument that does not have an associated convertible feature; and \$54.1 million to the equity component, representing the conversion option, which does not meet the criteria for separate accounting as a derivative as it is indexed to our own stock. ASU 2020-06 was adopted on January 1, 2021 as discussed in Note 2 "Basis of Presentation and Accounting Policies".

The effective interest rate of the 2027 Notes is 1.65%, which is imputed based on the amortization of the fair value of the embedded conversion option over the remaining term of the 2027 Note.

The 2027 Notes are convertible into common shares based on an initial conversion rate, subject to adjustment, of 2,477.65 shares per \$200,000 principal amount of notes (which represents an initial conversion price of \$80.7218 per share, or 6.2 million underlying shares). At conversion, we will settle the 2027 Notes by repaying the principal portion in cash and any excess of the conversion value over the principal amount in shares of common stock.

The notes may be redeemed at the option of each noteholder at their principal amount on December 17, 2025 or in connection with a change of control or delisting event.

The 2027 Notes are convertible in whole, but not in part, at the option of the noteholders on a net share settlement basis, at the prevailing conversion price in the following circumstances beginning after January 27, 2021 through June 16, 2027:

- if the last reported sale price of our common stock for at least 20-consecutive trading days during a period of 30-consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; or
- if we undergo certain fundamental changes, including a change of control, as defined in the agreement; or
- if parity event or trading price unavailability event, as the case maybe occurs during the period of 10 days, including the first business day following the relevant trading price notification date; or
- if we distribute assets or property to all or substantially all of the holders of our common stock and those assets or other property have a value of more than 25% of the average daily volume-weighted average trading price of our common stock for the prior 20 consecutive trading days; or
- in case of early redemption in respect of the outstanding notes at our option, where the conversion date falls in the period from (and including) the date on which the call notice is published to (and including) the 45th business day prior to the redemption date; or
- if we experience certain customary events of default, including defaults under certain other indebtedness, until such event of default has been cured or waived.

The noteholders may convert their notes at any time, without condition, on or after June 17, 2027 until the 45th business day prior to December 17, 2027.

No Contingent Conversion Conditions were triggered for the 2027 Notes as of September 30, 2021.

#### ***Cash Convertible Notes due 2021, 2023 and 2024***

On September 13, 2017, we issued \$400.0 million aggregate principal amount of Cash Convertible Senior Notes which is due in 2023 (2023 Notes). The net proceeds of the 2023 Notes were \$365.6 million, after payment of transaction costs and the net cost of the Call Spread Overlay described below.

On November 13, 2018, we issued \$500.0 million aggregate principal amount of Cash Convertible Senior Notes which is due in 2024 (2024 Notes). The net proceeds of the 2024 Notes were \$468.9 million, after payment of transaction costs and the net cost of the Call Spread Overlay described below.

On March 19, 2014, we issued Cash Convertible Senior Notes in two tranches including \$300.0 million due in 2021 (2021 Notes). In 2019, \$3.4 million was converted during the contingent conversion period. In 2020, a total of \$296.4 million of the 2021 Notes was repaid and the remaining \$0.2 million of 2021 Notes was repaid at the original maturity on March 19, 2021.

We refer to the 2021 Notes, 2023 Notes and 2024 Notes, collectively as the "Cash Convertible Notes."

Interest on the Cash Convertible Notes is payable semi-annually in arrears and will mature on the maturity date unless repurchased or converted with their terms prior to such date. The interest rate and corresponding maturity of each Note are summarized in the table below. The Cash Convertible Notes are solely convertible into cash in whole, but not in part, at the option of noteholders under the circumstances described below and during the contingent conversion periods as shown in the table below.



Cash Convertible Notes	Annual Interest Rate	Date of Interest Payments	Maturity Date	Contingent Conversion Period	Conversion Rate per \$200,000 Principal Amount
2021 Notes	0.875%	March 19 and September 19	March 19, 2021	April 29, 2014 to September 18, 2020	7,063.1647
2023 Notes	0.500%	March 13 and September 13	September 13, 2023	October 24, 2017 to March 13, 2023	4,829.7279
2024 Notes	1.000%	May 13 and November 13	November 13, 2024	December 24, 2018 to August 2, 2024	4,360.3098

Additionally, conversion may occur at any time following a Contingent Conversion Period through the fifth business day immediately preceding the applicable maturity date.

Upon conversion, noteholders will receive an amount in cash equal to the Cash Settlement Amount, calculated as described below. The Cash Convertible Notes are not convertible into shares of our common stock or any other securities.

Noteholders may convert the Cash Convertible Notes into cash at their option at any time during the Contingent Conversion Periods described above only under the following circumstances (Contingent Conversion Conditions):

- if the last reported sale price of our common stock for at least 20-consecutive trading days during a period of 30-consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
- if we undergo certain fundamental changes, including a change of control, as defined in the agreement;
- if parity event or trading price unavailability event, as the case may be occurs for the 2023 Notes and 2024 Notes during the period of 10 days, including the first business day following the relevant trading price notification date.
- if we elect to distribute assets or property to all or substantially all the holders of our common stock and those assets or other property have a value of more than 25% of the average daily volume-weighted average trading price of our common stock for the prior 20-consecutive trading days;
- if we elect to redeem the Cash Convertible Notes; or
- if we experience certain customary events of default, including defaults under certain other indebtedness until such event has been cured or waived or the payment of the Notes have been accelerated.

The Contingent Conversion Conditions in the 2023 Notes and 2024 Notes noted above have been analyzed under ASC 815, *Derivatives and Hedging*, and, based on our analysis, we determined that each of the embedded features listed above are clearly and closely related to the 2023 Notes and 2024 Notes (i.e., the host contracts). As a result, pursuant to the accounting provisions of ASC 815, *Derivatives and Hedging*, these features noted above are not required to be bifurcated as separate instruments.

Beginning on October 1, 2021 and ending at the close of business on December 31, 2021 (the “Relevant Fiscal Quarter”), the 2023 Notes may be surrendered for conversion. The 2023 Notes have become convertible pursuant to Section 12.01(b)(iv) of the indenture because the arithmetic mean of the last reported sale prices of our common stock, in each trading day in at least one 20 consecutive trading day period during the 30 consecutive trading day period ending on the last trading day of the preceding fiscal quarter, was greater than 130% of the conversion price in effect on such last trading day. The 2023 Notes will be convertible at a conversion ratio of 4,829.7279 per \$200,000 principal amount of 2023 Notes, which is equivalent to a conversion price of approximately \$41.4102 per share of our common stock.

No Contingent Conversion Conditions were triggered for the 2024 Notes as of September 30, 2021.

Upon conversion, holders are entitled to a cash payment (Cash Settlement Amount) equal to the average of the conversion rate multiplied by the daily volume-weighted average trading price for our common stock over a 50-day period. The conversion rate is subject to adjustment in certain instances but will not be adjusted for any accrued and unpaid interest. In addition, following the occurrence of certain corporate events that may occur prior to the applicable maturity date, we may be required to pay a cash make-whole premium by increasing the conversion rate for any holder who elects to convert Cash Convertible Notes in connection with the occurrence of such a corporate event.

We may redeem the Cash Convertible Notes in their entirety at a price equal to 100% of the principal amount of the applicable Cash Convertible Notes plus accrued interest at any time when 20% or less of the aggregate principal amount of the applicable Cash Convertible Notes originally issued remain outstanding.

Because the Cash Convertible Notes contain an embedded cash conversion option, we have determined that the embedded cash conversion option is a derivative financial instrument, which is required to be separated from the Cash Convertible Notes and accounted for separately as a derivative liability, with changes in fair value reported in our condensed consolidated statements of income until the cash conversion option transaction settles or expires. The initial fair value liability of the embedded cash conversion options for the 2021 Notes was \$54.0 million, \$74.5 million for the 2023 Notes, and \$98.5 million for the 2024 Notes, which simultaneously reduced the carrying value of the Cash

Convertible Notes (effectively an original issuance discount). For further discussion of the derivative financial instruments relating to the Cash Convertible Notes, refer to Note 8 "Derivatives and Hedging".

As noted above, the reduced carrying value on the Cash Convertible Notes resulted in a debt discount that is amortized to the principal amount through the recognition of non-cash interest expense using the effective interest method over the expected life of the debt, seven years for the 2021 Notes, and six years for the 2023 Notes and 2024 Notes. This resulted in our recognition of interest expense on the Cash Convertible Notes at an effective rate approximating what we would have incurred had nonconvertible debt with otherwise similar terms been issued. The effective interest rate of the 2021 Notes, 2023 Notes and 2024 Notes is 3.809%, 3.997% and 4.782%, respectively, which is imputed based on the amortization of the fair value of the embedded cash conversion option over the remaining term of the Cash Convertible Notes.

In connection with the issuance of the May 2014 Cash Convertible Senior Notes in two tranches, which included the 2021 Notes, we incurred approximately \$13.1 million in transaction costs. We incurred approximately \$6.2 million and \$5.7 million in transaction costs for the 2023 Notes and 2024 Notes, respectively. Such costs have been allocated to the Cash Convertible Notes and deferred and are being amortized to interest expense over the terms of the Cash Convertible Notes using the effective interest method.

#### *Cash Convertible Notes Call Spread Overlay*

Concurrent with the issuance of the Cash Convertible Notes, we entered into privately negotiated hedge transactions (Call Options) with, and issued warrants to purchase shares of our common stock (Warrants) to, certain financial institutions. We refer to the Call Options and Warrants collectively as the "Call Spread Overlay." The Call Options are intended to offset any cash payments payable by us in excess of the principal amount due upon any conversion of the Cash Convertible Notes. The Call Options are derivative financial instruments and are discussed further in Note 8 "Derivatives and Hedging." The Warrants are equity instruments and are further discussed in Note 12 "Equity."

Aside from the initial payment of a premium, we will not be required to make any cash payments under the Call Options, and will be entitled to receive an amount of cash, generally equal to the amount by which the market price per share of our common stock exceeds the exercise price of the Call Options during the relevant valuation period. The exercise price under the Call Options is initially equal to the conversion price of the Cash Convertible Notes.

The Warrants that were issued with our Cash Convertible Notes, could have a dilutive effect to the extent that the price of our common stock exceeds the applicable strike price of the Warrants. For each Warrant that is exercised, we will deliver to the holder a number of shares of our common stock equal to the amount by which the settlement price exceeds the exercise price, plus cash in lieu of any fractional shares. We will not receive any proceeds if the Warrants are exercised.

#### ***U.S. Private Placement***

In October 2012, we completed a private placement through the issuance of new senior unsecured notes at a total amount of \$400.0 million with a weighted average interest rate of 3.66% (settled on October 16, 2012). The notes were issued in three series: (1) \$73.0 million 7-year term due and paid in 2019 (3.19%); (2) \$300.0 million 10-year term due in October 16, 2022 (3.75%); and (3) \$27.0 million 12-year term due in October 16, 2024 (3.90%). We paid \$2.1 million in debt issuance costs which will be amortized through interest expense using the effective interest method over the lifetime of the notes. The note purchase agreement contains certain financial and non-financial covenants, including but not limited to, restrictions on priority indebtedness and the maintenance of certain financial ratios. We were in compliance with these covenants at September 30, 2021. During 2014, we entered into interest rate swaps, which effectively fixed the fair value of \$200.0 million of this debt, which was reduced to \$127.0 million following the 2019 \$73.0 million repayment. These interest rate swaps qualify for hedge accounting as fair value hedges as described in Note 8 "Derivatives and Hedging".

#### ***German Private Placement (Schuldschein)***

In 2017, we completed a German private placement bond ("Schuldschein") which was issued in several tranches totaling \$331.1 million due in various periods through 2027. In the first quarter of 2021, we repaid \$41.1 million for two tranches that matured. The Schuldschein consists of U.S. dollar and Euro denominated tranches. The Euro tranches are designated as a foreign currency non-derivative hedging instrument that qualifies as a net investment hedge as described in Note 8 "Derivatives and Hedging." Based on the spot rate method, the change in the carrying value of the Euro denominated tranches attributed to the net investment hedge as of September 30, 2021 totaled \$7.7 million of unrealized loss and is recorded in equity. We paid \$1.2 million in debt issuance costs which are being amortized through interest expense using the effective interest method over the lifetime of the notes.

A summary of the tranches as of September 30, 2021 and December 31, 2020 is as follows:

Currency	Notional Amount	Interest Rate	Maturity	Carrying Value (in thousands) as of	
				September 30, 2021	December 31, 2020
EUR	€11.5 million	Fixed 0.4%	March 2021	\$ —	\$ 14,115
EUR	€23.0 million	Floating EURIBOR + 0.4%	March 2021	—	28,224
EUR	€21.5 million	Fixed 0.68%	October 2022	<b>24,882</b>	26,361
EUR	€64.5 million	Floating EURIBOR + 0.5%	October 2022	<b>74,644</b>	79,083
USD	\$45.0 million	Floating LIBOR + 1.2%	October 2022	<b>44,974</b>	44,948
EUR	€25.0 million	Floating EURIBOR + 0.5%	October 2022	<b>28,923</b>	30,642
EUR	€64.0 million	Fixed 1.09%	June 2024	<b>74,018</b>	78,429
EUR	€31.0 million	Floating EURIBOR + 0.7%	June 2024	<b>35,852</b>	37,989
EUR	€14.5 million	Fixed 1.61%	June 2027	<b>16,759</b>	17,760
				<b>\$ 300,052</b>	<b>\$ 357,551</b>

The financial markets regulators in the United Kingdom and the Eurozone have passed regulations wherein non-dollar LIBORs and one-week and two-month USD LIBOR will end as of Dec 31, 2021, while the remaining USD LIBOR tenors will end as of June 30, 2023. Market participants and regulators are working on establishing new interest rate benchmarks. While the outcome of this work is not clear yet, the USD tranche of the Schuldschein and our interest rate swaps continue to make reference to the current LIBOR benchmark rate. These agreements contain language for the determination of interest rates in case the benchmark rate is not available. However, it appears likely that the agreements will need to be adjusted in line with still to be developed market practice once new benchmark rates become available.

### **Revolving Credit Facility**

Our credit facilities available and undrawn at September 30, 2021 total €427.0 million (approximately \$494.4 million). This includes a €400.0 million syndicated ESG-linked revolving credit facility expiring December 2023 and three other lines of credit amounting to €27.0 million with no expiration date. The €400.0 million facility can be utilized in Euro and bears interest of 0.550% to 1.500% above EURIBOR, and is offered with interest periods of one, three or six months. The commitment fee is calculated based on 35% of the applicable margin. The revolving facility agreement contains certain financial and non-financial covenants, including but not limited to, restrictions on the encumbrance of assets and the maintenance of certain financial ratios. We were in compliance with these covenants at September 30, 2021. The credit facilities are for general corporate purposes and no amounts were utilized at September 30, 2021.

## **8. DERIVATIVES AND HEDGING**

### **Objective and Strategy**

In the ordinary course of business, we use derivative instruments, including swaps, forwards and/or options, to manage potential losses from foreign currency exposures and interest bearing assets or liabilities. The principal objective of such derivative instruments is to minimize the risks and/or costs associated with our global financial and operating activities. We do not utilize derivative or other financial instruments for trading or other speculative purposes. We recognize all derivatives as either assets or liabilities on the balance sheet on a gross basis, measure those instruments at fair value and recognize the change in fair value in earnings in the period of change, unless the derivative qualifies as an effective hedge that offsets certain exposures. We have agreed with almost all of our counterparties with whom we had entered into cross-currency swaps, interest rate swaps or foreign exchange contracts, to enter into bilateral collateralization contracts under which we will receive or provide cash collateral, as the case may be, for the net position with each of these counterparties. As of September 30, 2021, cash collateral positions consisted of \$20.2 million recorded in accrued and other current liabilities and \$8.7 million recorded in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. As of December 31, 2020, we had cash collateral positions consisting of \$0.6 million recorded in accrued and other current liabilities and \$56.1 million recorded in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets.

### **Non-Derivative Hedging Instrument**

#### *Net Investment Hedge*

We are party to a foreign currency non-derivative hedging instrument that is designated and qualifies as net investment hedge. The objective of the hedge is to protect part of the net investment in foreign operations against adverse changes in

the exchange rate between the Euro and the functional currency of the U.S. dollar. The non-derivative hedging instrument is the German private corporate bond ("Schuldschein") which was issued in the total amount of \$331.1 million as described in Note 7 "Debt". Of the \$331.1 million, which is held in both U.S. dollars and Euros, €255.0 million was designated as the hedging instrument as of December 31, 2020 against a portion of our Euro net investments in our foreign operations. As further described in Note 7, two tranches of the Schuldschein matured and were paid during the first quarter of 2021 and as a result, €220.5 million remained designated as a hedging instrument as of September 30, 2021. The relative changes in both the hedged item and hedging instrument are calculated by applying the change in spot rate between two assessment dates against the respective notional amount. The effective portion of the hedge is recorded in the cumulative translation adjustment account within other accumulated comprehensive loss. Based on the spot rate method, the unrealized loss recorded in equity as of September 30, 2021 and December 31, 2020 is \$7.7 million and \$26.9 million, respectively. Since we are using the debt as the hedging instrument, which is also remeasured based on the spot rate method, there is no hedge ineffectiveness related to the net investment hedge as of September 30, 2021 and December 31, 2020.

### ***Derivatives Designated as Hedging Instruments***

#### *Cash Flow Hedges*

As of September 30, 2021 and December 31, 2020, we held derivative instruments that are designated and qualify as cash flow hedges, where the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive loss and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. To date, we have not recorded any hedge ineffectiveness related to any cash-flow hedges in earnings. Based on their valuation as of September 30, 2021, we expect approximately \$4.1 million of derivative losses included in accumulated other comprehensive loss will be reclassified into income during the next 12 months. The cash flows derived from derivatives are classified in the condensed consolidated statements of cash flows in the same category as the condensed consolidated balance sheets account of the underlying item.

We use interest rate derivative contracts to align our portfolio of interest bearing assets and liabilities with our risk management objectives. We are party to five cross currency interest rate swaps through 2025 for a total notional amount of €180.0 million which qualify for hedge accounting as cash flow hedges. We determined that no ineffectiveness exists related to these swaps. As of September 30, 2021 and December 31, 2020, interest receivables of \$0.4 million and \$1.1 million, respectively are recorded in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets.

#### *Fair Value Hedges*

As of September 30, 2021 and December 31, 2020, we held derivative instruments that qualify for hedge accounting as fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the effective portion of the gain or loss on the derivative is reflected in earnings. This effect on earnings is offset by the change in the fair value of the hedged item attributable to the risk being hedged that is also recorded in earnings. To date, there has been no ineffectiveness. The cash flows derived from derivatives are classified in the condensed consolidated statements of cash flows in the same category as the condensed consolidated balance sheets account of the underlying item.

We hold interest rate swaps which effectively fix the fair value of a portion of our fixed rate private placement debt and qualify for hedge accounting as fair value hedges. We determined that no ineffectiveness exists related to these swaps. As of September 30, 2021 and December 31, 2020, interest receivables of \$1.4 million and \$0.6 million, respectively, are recorded in prepaid and other current assets in the accompanying condensed consolidated balance sheets.

### ***Derivatives Not Designated as Hedging Instruments***

#### *Call Options*

We entered into Call Options which, along with the sale of the Warrants, represent the Call Spread Overlay entered into in connection with the Cash Convertible Notes and which are more fully described in Note 7 "Debt". In these transactions, the Call Options are intended to address the equity price risk inherent in the cash conversion feature of each instrument by offsetting cash payments in excess of the principal amount due upon any conversion of the Cash Convertible Notes.

Aside from the initial payment of premiums for the Call Options, we will not be required to make any cash payments under the Call Options. We will, however, be entitled to receive under the terms of the Call Options, an amount of cash generally equal to the amount by which the market price per share of our common stock exceeds the exercise price of the Call Options during the relevant valuation period. The exercise price under the Call Options is equal to the conversion price of the Cash Convertible Notes.

The Call Options, for which our common stock is the underlying security, are derivative assets that require mark-to-market accounting treatment. The Call Options are measured and reported at fair value on a recurring basis, within Level 2 of the fair value hierarchy. The change in fair value is recognized immediately in our condensed consolidated statements of income in other income (expense), net.

#### *Cash Convertible Notes Embedded Cash Conversion Option*

The embedded cash conversion option within the Cash Convertible Notes discussed in Note 7 "Debt" is required to be separated from the Cash Convertible Notes and accounted for separately as a derivative liability, with changes in fair value reported in our condensed consolidated statements of income in other income (expense), net until the cash conversion option settles or expires. The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 2 of the fair value hierarchy.

Because the terms of the Cash Convertible Notes' embedded cash conversion option are substantially similar to those of the Call Options, discussed above, we expect the effect on earnings from these two derivative instruments to mostly offset each other.

#### *Foreign Exchange Contracts*

As a globally active enterprise, we are subject to risks associated with fluctuations in foreign currencies in our ordinary operations. This includes foreign currency-denominated receivables, payables, debt, and other balance sheet positions including intercompany items. We manage balance sheet exposure on a group-wide basis using foreign exchange forward contracts, foreign exchange options and cross-currency swaps.

We are party to various foreign exchange forward, option and swap arrangements which had, at both September 30, 2021 and December 31, 2020, aggregate notional values of \$1.3 billion, which expire at various dates through February 2022. The transactions have been entered into to offset the effects from short-term balance sheet exposure to foreign currency exchange risk. Changes in the fair value of these arrangements have been recognized in other income (expense), net.

#### **Fair Values of Derivative Instruments**

The following table summarizes the fair value amounts of derivative instruments as of September 30, 2021 and December 31, 2020. The current assets are included in prepaid expenses and other current assets and the current liabilities are included in accrued and other current liabilities in the accompanying condensed consolidated balance sheets.

(in thousands)	As of September 30, 2021		As of December 31, 2020	
	Current Asset	Long-Term Asset	Current Asset	Long-Term Asset
<b>Assets:</b>				
<b>Derivative instruments designated as hedges</b>				
Interest rate contracts - fair value hedge <sup>(1)</sup>	\$ —	\$ 2,960	\$ —	\$ 5,042
Total derivative instruments designated as hedges	\$ —	\$ 2,960	\$ —	\$ 5,042
<b>Undesignated derivative instruments</b>				
Equity options	\$ 151,746	\$ 167,092	\$ 2,415	\$ 374,038
Foreign exchange forwards and options	30,736	—	11,712	—
Total undesignated derivative instruments	\$ 182,482	\$ 167,092	\$ 14,127	\$ 374,038
<b>Total Derivative Assets</b>	<b>\$ 182,482</b>	<b>\$ 170,052</b>	<b>\$ 14,127</b>	<b>\$ 379,080</b>

(in thousands)	As of September 30, 2021		As of December 31, 2020	
	Current Liability	Long-Term Liability	Current Liability	Long-Term Liability
<b>Liabilities:</b>				
<b>Derivative instruments designated as hedges</b>				
Interest rate contracts - cash flow hedge <sup>(1)</sup>	\$ —	\$ (4,324)	\$ —	\$ (17,409)
Total derivative instruments designated as hedges	\$ —	\$ (4,324)	\$ —	\$ (17,409)
<b>Undesignated derivative instruments</b>				
Equity options	\$ (152,307)	\$ (167,851)	\$ (5,966)	\$ (376,046)
Foreign exchange forwards and options	(7,049)	—	(45,498)	—
Total undesignated derivative instruments	\$ (159,356)	\$ (167,851)	\$ (51,464)	\$ (376,046)
<b>Total Derivative Liabilities</b>	<b>\$ (159,356)</b>	<b>\$ (172,175)</b>	<b>\$ (51,464)</b>	<b>\$ (393,455)</b>

<sup>(1)</sup> The fair value amounts for the interest rate contracts do not include accrued interest.

### Gains and Losses on Derivative Instruments

The following tables summarize the gains and losses on derivative instruments for the three- and nine-month periods ended September 30, 2021 and 2020:

(in thousands)	Three months ended		Nine months ended	
	September 30,		September 30,	
	2021	2020	2021	2020
Total amounts presented in the Condensed Consolidated Statements of Income in which the effects of cash flow and fair value hedges are recorded	Other income (expense), net	Other income (expense), net	Other income (expense), net	Other income (expense), net
	\$ 30,894	\$ (267)	\$ 38,558	\$ (1,514)

### Gains (Losses) on Derivatives in Cash Flow Hedges

Interest rate contracts				
Amount of loss reclassified from accumulated other comprehensive loss	\$ (5,490)	\$ 9,180	\$ (12,456)	\$ 8,532
Amounts excluded from effectiveness testing	—	—	—	—

### Gains (Losses) on Derivatives in Fair Value Hedges

Interest rate contracts				
Hedged item	655	626	2,082	(3,186)
Derivatives designated as hedging instruments	(655)	(626)	(2,082)	3,186

### Gains (Losses) Derivatives Not Designated as Hedging Instruments

Equity options	56,141	235,092	(57,615)	279,421
Cash convertible notes embedded cash conversion option	(56,420)	(235,777)	61,854	(280,765)
Foreign exchange forwards and options	6,776	20,411	18,657	4,408
<b>Total gain</b>	<b>\$ 1,007</b>	<b>\$ 28,906</b>	<b>\$ 10,440</b>	<b>\$ 11,596</b>

### **Balance Sheet Line Items in which the Hedged Item is Included**

The following tables summarizes the balance sheet line items in which the hedged item is included as of September 30, 2021 and December 31, 2020:

(in thousands)	Carrying Amount of the Hedged Assets (Liabilities)		Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets (Liabilities)	
	September 30, 2021	December 31, 2020	September 30, 2021	December 31, 2020
Long-term debt	\$ (129,889)	\$ (131,923)	\$ 2,960	\$ 5,042

## **9. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS**

The following discusses our non-marketable investments, marketable investments, and the realized and unrealized gains and losses on these investments.

Assets and liabilities are measured at fair value according to a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:

*Level 1.* Observable inputs, such as quoted prices in active markets;

*Level 2.* Inputs, other than the quoted price in active markets, that are observable either directly or indirectly; and

*Level 3.* Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Our assets and liabilities measured at fair value on a recurring basis consist of marketable securities discussed in Note 5 "Investments", which are classified in Level 1, short-term investments, which are classified in Level 2 of the fair value hierarchy, derivative contracts used to hedge currency and interest rate risk and derivative financial instruments entered into in connection with the Cash Convertible Notes discussed in Note 7 "Debt", which are classified in Level 2 of the fair value hierarchy, contingent consideration accruals which are classified in Level 3 of the fair value hierarchy, and are shown in the tables below and non-marketable equity securities remeasured as of September 30, 2021 and December 31, 2020 which are classified within Level 3 in the fair value hierarchy. There were no transfers between levels during the nine months ended September 30, 2021.

In determining fair value for Level 2 instruments, we apply a market approach, using quoted active market prices relevant to the particular instrument under valuation, giving consideration to the credit risk of both the respective counterparty to the contract and the Company. To determine our credit risk, we estimated our credit rating by benchmarking the price of outstanding debt to publicly-available comparable data from rated companies. Using the estimated rating, our credit risk was quantified by reference to publicly-traded debt with a corresponding rating. The Level 2 derivative financial instruments include the Call Options asset and the embedded conversion option liability. See Note 7 "Debt" and Note 8 "Derivatives and Hedging" for further information. The derivatives are not actively traded and are valued based on an option pricing model that uses observable market data for inputs. Significant market data inputs used to determine fair values included our common stock price, the risk-free interest rate, and the implied volatility of our common stock. The Call Options asset and the embedded cash conversion option liability were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is substantially mitigated.

Our Level 3 instruments include non-marketable equity security investments. Under the measurement alternative, the carrying value is measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach as of the transaction date.

Our Level 3 instruments also include contingent consideration liabilities. We value contingent consideration liabilities using unobservable inputs, applying the income approach, such as the discounted cash flow technique, or the probability-weighted scenario method. Contingent consideration arrangements obligate us to pay the sellers of an acquired entity if specified future events occur or conditions are met such as the achievement of technological or revenue milestones. We use various key assumptions, such as the probability of achievement of the milestones (0% to 100%) and the discount rate (between 6.5% and 6.9%), to represent the non-performing risk factors and time value when applying the income approach. We regularly review the fair value of the contingent consideration, and reflect any change in the accrual in the condensed consolidated statements of income in the line items commensurate with the underlying nature of milestone arrangements.

The following table presents our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis:

(in thousands)	As of September 30, 2021				As of December 31, 2020			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
<b>Assets:</b>								
Short-term investments	\$ —	\$ 339,777	\$ —	\$ 339,777	\$ —	\$ —	\$ —	\$ —
Marketable equity securities	—	—	—	—	117,515	—	—	117,515
Non-marketable equity securities	—	—	4,050	4,050	—	—	4,142	4,142
Equity options	—	318,838	—	318,838	—	376,453	—	376,453
Foreign exchange forwards and options	—	30,736	—	30,736	—	11,712	—	11,712
Interest rate contracts	—	2,960	—	2,960	—	5,042	—	5,042
	<u>\$ —</u>	<u>\$ 692,311</u>	<u>\$ 4,050</u>	<u>\$ 696,361</u>	<u>\$ 117,515</u>	<u>\$ 393,207</u>	<u>\$ 4,142</u>	<u>\$ 514,864</u>
<b>Liabilities:</b>								
Foreign exchange forwards and options	\$ —	\$ (7,049)	\$ —	\$ (7,049)	\$ —	\$ (45,498)	\$ —	\$ (45,498)
Interest rate contracts	—	(4,324)	—	(4,324)	—	(17,409)	—	(17,409)
Cash conversion option	—	(320,158)	—	(320,158)	—	(382,012)	—	(382,012)
Contingent consideration	—	—	(23,888)	(23,888)	—	—	(23,593)	(23,593)
	<u>\$ —</u>	<u>\$ (331,531)</u>	<u>\$ (23,888)</u>	<u>\$ (355,419)</u>	<u>\$ —</u>	<u>\$ (444,919)</u>	<u>\$ (23,593)</u>	<u>\$ (468,512)</u>

Refer to Note 5 "Investments" for the change in non-marketable equity securities with Level 3 inputs during the nine-month periods ended September 30, 2021 and 2020. For contingent consideration liabilities with Level 3 inputs, the following table summarizes the activity for the nine-month period ended September 30, 2021:

(in thousands)	2021
Balance at beginning of year	\$ (23,593)
Additions	(295)
Balance at end of period	<u>\$ (23,888)</u>

As of September 30, 2021, \$23.9 million was accrued for contingent consideration and is included in accrued and other current liabilities in the accompanying condensed consolidated balance sheet. For the nine-month period ended September 30, 2021, the \$0.3 million of additions are related to the time value increases of existing contingent consideration liabilities.

The carrying values of financial instruments, including cash and cash equivalents, short-term deposits, accounts receivable, accounts payable and other accrued liabilities, approximate their fair values due to their short-term maturities. The estimated fair value of long-term debt as disclosed in Note 7 "Debt" was based on current interest rates for similar types of borrowings. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future.

The fair values of the financial instruments are presented in Note 7 "Debt" and were determined as follows:

*Cash Convertible Notes and Convertible Notes:* Fair value is based on using available over-the-counter market information on the Cash Convertible Notes due in 2023 and 2024 as well as the Convertible Notes due in 2027.

*U.S. Private Placement:* Fair value of the outstanding bonds is based on an estimation using the changes in the U.S. Treasury rates.

*German Private Placement:* Fair value is based on an estimation using changes in the euro swap rates.

There were no adjustments in the three- and nine-month periods ended September 30, 2021 and 2020 for nonfinancial assets or liabilities required to be measured at fair value on a nonrecurring basis.



## 10. INCOME TAXES

The quarterly provision for income taxes is based upon the estimated annual effective tax rate for the year, applied to the current period ordinary income before tax plus the tax effect of any discrete items. Our operating subsidiaries are exposed to statutory tax rates ranging from zero to 35%. Fluctuations in the distribution of pre-tax loss or income among our operating subsidiaries can lead to fluctuations of the effective tax rate in the condensed consolidated financial statements. In the third quarters of 2021 and 2020, our effective tax rates were 12.1% and 39.4%, respectively. In the nine-month periods ended September 30, 2021 and 2020, the effective tax rates were 16.7% and 19.9%. The effective tax rate in 2021 reflects higher operating income in the current year due primarily to the growth trends in non-COVID products and continuing demand for solutions used in COVID-19 testing. Additionally, we record partial tax exemptions on foreign income primarily derived from operations in Germany, the Netherlands and Singapore. These foreign tax benefits are due to a combination of favorable tax laws, rules, rulings, and exemptions in these jurisdictions, including intercompany foreign royalty income in Germany which is statutorily exempt from trade tax. Further, we have intercompany financing arrangements in which the intercompany income is nontaxable in Dubai.

We assess uncertain tax positions in accordance with ASC 740 (ASC 740-10 *Accounting for Uncertainties in Tax*). At September 30, 2021, our gross unrecognized tax benefits totaled approximately \$100.7 million which, if recognized, would favorably impact our effective tax rate in the periods in which they are recognized. It is reasonably possible that approximately \$35.9 million of the unrecognized tax benefits may be released during the next 12 months due to lapse of statutes of limitations or settlements with tax authorities. However, various events could cause our current expectations to change in the future. While we believe our allowance for all income tax contingencies are adequate, the final resolution of these issues, if unfavorable, could have a material impact on the consolidated financial statements. We cannot reasonably estimate the range of the potential outcomes of these matters.

The United States Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted on March 27, 2020. The CARES Act and related notices include several significant provisions, including delaying certain payroll tax payments and mandatory transition tax payments under the Tax Cuts and Jobs Act as well as an extension of the net operating losses (NOL) carryback period to five years. At present, the primary impact from the CARES Act is that it allowed us to carry back U.S. NOLs for five years. We will continue to monitor and assess the impact the CARES Act and similar legislation in other countries may have on our business and financial results.

We conduct business globally and, as a result, file numerous consolidated and separate income tax returns in the Netherlands, Germany, and the U.S. federal jurisdiction, as well as in various other state and foreign jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. Tax years in the Netherlands are potentially open back to 2009 for income tax examinations by tax authorities. The U.S. consolidated group is open to Federal and most state income tax examinations by the tax authorities beginning with the 2017 tax year. Our subsidiaries, with few exceptions, are no longer open to income tax examinations by tax authorities for years before 2016. The German tax authorities have commenced an audit for the 2014-2016 tax years.

As of September 30, 2021, residual Netherlands income taxes have not been provided on the undistributed earnings of the majority of our foreign subsidiaries as these earnings are considered to be either permanently reinvested or can be repatriated tax free under the Dutch participation exemption.

## 11. INVENTORIES

The components of inventories consist of the following as of September 30, 2021 and December 31, 2020:

(in thousands)	September 30, 2021	December 31, 2020
Raw materials	\$ 89,562	\$ 65,449
Work in process	69,498	74,398
Finished goods	176,631	151,334
Total inventories, net	<u>\$ 335,691</u>	<u>\$ 291,181</u>

## 12. EQUITY

### Issuance and Conversion of Warrants

In connection with the issuance of the Cash Convertible Notes as described in Note 7 "Debt", we issued Warrants as summarized in the table below. The number of warrants and exercise prices are subject to customary adjustments under certain circumstances. The proceeds, net of issuance costs, from the sale of the Warrants are included as additional paid in capital in the accompanying condensed consolidated balance sheets.

Cash convertible notes	Issued on	Number of share warrants (in millions)	Exercise price per share	Proceeds from issuance of warrants, net of issuance costs (in millions)	Warrants expire over a period of 50 trading days beginning on
2023	September 13, 2017	9.7	\$49.9775	\$45.3	June 26, 2023
2024	November 13, 2018	10.9	\$50.2947	\$72.4	August 27, 2024

The Warrants are exercisable only upon expiration. For each Warrant that is exercised, we will deliver to the holder a number of shares of our common stock equal to the amount by which the settlement price exceeds the exercise price, divided by the settlement price, plus cash in lieu of any fractional shares. The Warrants could separately have a dilutive effect on shares of our common stock to the extent that the market value per share of our common stock exceeds the applicable exercise price of the Warrants (as measured under the terms of the Warrants).

During the three- and nine-month periods ended September 30, 2020, 0.3 million common shares were issued in connection with the early conversion of 0.8 million warrants related to the 2021 Notes which resulted in a \$3.0 million decrease to additional paid in capital.

### Share Repurchase Programs

On July 12, 2021, we announced our seventh share repurchase program of up to \$100 million of our common shares. During the three months ended September 30, 2021, we repurchased 1.6 million QIAGEN shares for \$83.8 million (including transaction costs). In October 2021, we repurchased 0.3 million QIAGEN shares for \$16.1 million (including transaction costs). This program has therefore concluded on October 29, 2021.

On May 6, 2019, we announced our sixth share repurchase program of up to \$100 million of our common shares. During 2020, we repurchased 1.3 million QIAGEN shares for \$64.0 million (including transaction costs). This program ended on December 17, 2020.

The cost of repurchased shares is included in treasury stock and reported as a reduction in total equity when a repurchase occurs. Repurchased shares will be held in treasury in order to satisfy various obligations, which include exchangeable debt instruments, warrants and employee share-based remuneration plans.

### Accumulated Other Comprehensive Loss

The following table is a summary of the components of accumulated other comprehensive loss as of September 30, 2021 and December 31, 2020:

(in thousands)	September 30, 2021	December 31, 2020
Net unrealized loss on hedging contracts, net of tax	\$ (3,633)	\$ (23,268)
Net unrealized loss on pension, net of tax	(599)	(599)
Foreign currency effects from intercompany long-term investment transactions, net of tax benefit of \$11.3 million and \$10.7 million in 2021 and 2020, respectively	(27,546)	(25,717)
Foreign currency translation adjustments	(259,823)	(194,238)
Accumulated other comprehensive loss	<u>\$ (291,601)</u>	<u>\$ (243,822)</u>

## 13. REVENUE

### Contract Estimates

The majority of our revenue is derived from contracts (i) with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount in which we have the right to invoice as product is delivered. We have elected the practical expedient not to disclose the value of remaining performance obligations associated with these types of contracts.

However, we have certain companion diagnostic co-development contracts to provide research and development activities in which our performance obligations extend over multiple years. As of September 30, 2021, we had \$62.2 million of remaining performance obligations for which the transaction price is not constrained related to these contracts which we expect to recognize over the next 12 to 18 months.

Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material.

### **Contract Balances**

The timing of revenue recognition, billings and cash collections can result in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) in the condensed consolidated balance sheet.

Contract assets as of September 30, 2021 and December 31, 2020 totaled \$12.7 million and \$8.5 million, respectively, and are included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets and relate to the companion diagnostic co-development contracts discussed above.

Contract liabilities primarily relate to non-cancellable advances or deposits received from customers before revenue is recognized and is primarily related to instrument service and Software as a Service (SaaS) arrangements. As of September 30, 2021 and December 31, 2020, contract liabilities totaled \$73.3 million and \$68.9 million, respectively, of which \$61.9 million and \$57.1 million is included in accrued and other current liabilities, respectively, and \$11.4 million and \$11.8 million in included in other long-term liabilities, respectively. During the three and nine months ended September 30, 2021 and 2020, we satisfied the associated performance obligations and recognized revenue of \$12.5 million and \$47.9 million, and \$13.7 million and \$45.8 million, respectively, related to advance customer payments previously received.

### **Disaggregation of Revenue**

We disaggregate our revenue based on product type and customer class, product category and geography as shown in the tables below for the three- and nine-month periods ended September 30, 2021 and 2020:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2020	2021	2020
Consumables and related revenues	\$ 253,184	\$ 206,497	\$ 738,063	\$ 524,204
Instruments	26,001	30,680	92,115	92,899
Molecular Diagnostics	279,185	237,177	830,178	617,103
Consumables and related revenues	219,611	213,453	731,031	597,143
Instruments	35,949	33,133	108,050	84,866
Life Sciences	255,560	246,586	839,081	682,009
Total	\$ 534,745	\$ 483,763	\$ 1,669,259	\$ 1,299,112

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2020	2021	2020
Sample technologies	\$ 202,464	213,863	\$ 632,226	\$ 568,130
Diagnostic solutions	162,166	118,796	466,115	301,995
PCR / Nucleic acid amplification	98,500	95,879	323,891	255,200
Genomics / NGS	52,994	36,795	182,917	115,667
Other	18,621	18,430	64,110	58,120
Total	\$ 534,745	\$ 483,763	\$ 1,669,259	\$ 1,299,112

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2020	2021	2020
Americas	\$ 247,936	\$ 227,327	\$ 748,858	\$ 578,383
Europe, Middle East and Africa	174,317	164,095	594,925	457,003
Asia Pacific and Rest of World	112,492	92,341	325,476	263,726
Total	<u>\$ 534,745</u>	<u>\$ 483,763</u>	<u>\$ 1,669,259</u>	<u>\$ 1,299,112</u>

#### 14. EARNINGS PER COMMON SHARE

We present basic and diluted earnings per share. Basic earnings per share is calculated by dividing the net income by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that would occur if all “in the money” securities to issue common shares were exercised.

The following table for the three- and nine-month periods ended September 30, 2021 and 2020 summarizes the information used to compute earnings per common share:

(in thousands, except per share data)	Three months ended September 30,	
	2021	2020
Net income	<u>\$ 133,139</u>	<u>\$ 16,910</u>
Weighted average number of common shares used to compute basic net income per common share	228,060	228,733
Dilutive effect of stock options and restricted stock units	3,143	3,580
Dilutive effect of outstanding warrants	926	3,472
Weighted average number of common shares used to compute diluted net income per common share	<u>232,129</u>	<u>235,785</u>
Outstanding options and awards having no dilutive effect, not included in above calculation	—	—
Outstanding warrants having no dilutive effect, not included in above calculation	<u>19,635</u>	<u>26,924</u>
Basic earnings per common share	<u>\$ 0.58</u>	<u>\$ 0.07</u>
Diluted earnings per common share	<u>\$ 0.57</u>	<u>\$ 0.07</u>
(in thousands, except per share data)	Nine months ended September 30,	
	2021	2020
Net income	<u>\$ 383,413</u>	<u>\$ 146,503</u>
Weighted average number of common shares used to compute basic net income per common share	228,277	228,378
Dilutive effect of stock options and restricted stock units	3,481	3,174
Dilutive effect of outstanding warrants	367	2,456
Weighted average number of common shares used to compute diluted net income per common share	<u>232,125</u>	<u>234,008</u>
Outstanding options and awards having no dilutive effect, not included in above calculation	<u>3</u>	<u>15</u>
Outstanding warrants having no dilutive effect, not included in above calculation	<u>20,193</u>	<u>28,398</u>
Basic earnings per common share	<u>\$ 1.68</u>	<u>\$ 0.64</u>
Diluted earnings per common share	<u>\$ 1.65</u>	<u>\$ 0.63</u>

For purposes of considering the 2027 Notes in determining diluted earnings per common share, only an excess of the conversion value over the principal amount would have a dilutive impact using the treasury stock method. Since the 2027 Notes were out of the money and anti-dilutive during the period from January 1, 2021 through September 30, 2021, they were excluded from the diluted earnings per common share calculations in 2021.

## 15. COMMITMENTS AND CONTINGENCIES

---

### ***Contingent Consideration Commitments***

Pursuant to the purchase agreements for certain acquisitions and other contractual arrangements, we could be required to make additional contingent cash payments totaling up to \$26.6 million in 2022 based on the achievement of certain revenue and operating results milestones.

Of the \$26.6 million total contingent obligation as discussed further in Note 9 "Financial Instruments and Fair Value Measurements," we have assessed the fair value at September 30, 2021 to be \$23.9 million which is included in accrued and other current liabilities in the accompanying condensed consolidated balance sheet. At December 31, 2020, the fair value of contingent consideration was \$23.6 million.

### ***Contingencies***

In the ordinary course of business, we provide a warranty to customers that our products are free of defects and will conform to published specifications. Generally, the applicable product warranty period is one year from the date of delivery of the product to the customer or of site acceptance, if required. Additionally, we typically provide limited warranties with respect to our services. We provide for estimated warranty costs at the time of the product sale. We believe our warranty reserves of \$5.9 million and \$4.8 million as of September 30, 2021 and December 31, 2020, respectively, appropriately reflect the estimated cost of such warranty obligations.

### ***Litigation***

From time to time, we may be party to legal proceedings incidental to our business. As of September 30, 2021, certain claims, suits or legal proceedings arising out of the normal course of business have been filed or were pending against QIAGEN or our subsidiaries. These matters have arisen in the ordinary course and conduct of business, as well as through acquisition. Although it is not possible to predict the outcome of such litigation, we assess the degree of probability and evaluate the reasonably possible losses that we could incur as a result of these matters. We accrue for any estimated loss when it is probable that a liability has been incurred and the amount of probable loss can be estimated.

Litigation accruals recorded in accrued and other current liabilities totaled \$58.8 million and \$5.2 million as of September 30, 2021 and December 31, 2020, respectively.

ArcherDx spun out as an independent company in conjunction with QIAGEN's acquisition of Enzymatics in 2015. In 2018, ArcherDx (recently acquired by Invitae) and Massachusetts General Hospital (MGH) sued QIAGEN for patent infringement. In August 2021, a Federal jury ruled that QIAGEN infringed two patents owned by ArcherDx and awarded damages of \$4.7 million. We plan to appeal the verdict as soon as the final verdict is entered. As of September 30, 2021, current accrued liabilities include \$4.7 million for this matter, which was expensed in Restructuring, acquisition, integration and other, net, in the three months ended September 30, 2021.

In September 2020, QIAGEN acquired NeuMoDx. As part of the purchase, QIAGEN also acquired preexisting contingencies and became defendant in ongoing litigation matters pertaining to preexisting claims made by Becton Dickinson (BD) and subsidiaries over patent infringement. In September 2021, through mediation, the parties reached a preliminary settlement which included a payment of \$53.0 million to BD for the past infringements of NeuMoDx prior to QIAGEN's acquisition. As of September 30, 2021, current accrued liabilities include \$53.0 million for this matter, as discussed in Note 3. On November 5, 2021, QIAGEN and BD reached an agreement to settle their ongoing litigation in the U.S. District Court of the District of Delaware and certain inter partes review proceedings. As part of the settlement, all claims asserted against QIAGEN, as well as counterclaims asserted against BD, were dismissed. QIAGEN will provide financial consideration to BD. In addition to patent infringement allegations, the litigation involved trade secret misappropriation and other non-patent claims relating to NeuMoDx and former NeuMoDx officers, before the acquisition by QIAGEN.

A total of \$1.1 million is accrued as of September 30, 2021 for other matters. The estimated amount of a range of possible losses for these matters as of September 30, 2021, is between \$0.2 million and \$2.1 million. Based on the facts known to QIAGEN and after consultation with legal counsel, management believes that such litigation will not have a material adverse effect on our financial position or results of operations above the amounts accrued. However, the outcome of these matters is ultimately uncertain, thus any settlements or judgments against us in excess of management's expectations could have a material adverse effect on our financial position, results of operations or cash flows.

## 16. SHARE-BASED COMPENSATION

### Stock Units

Stock units represent rights to receive our common shares at a future date and include restricted stock units which are subject to time-based vesting only and performance stock units which include performance conditions in addition to time-based vesting. Shares are issued on the vesting dates net of the applicable statutory tax withholding to be paid by us on behalf of our employees. As a result, fewer shares are issued than the number of stock units outstanding. We record a liability for the tax withholding to be paid by us as a reduction to treasury shares.

During the three- and nine-month periods ended September 30, 2021, we granted 17.5 thousand and 0.7 million stock awards compared to 5.5 thousand and 1.0 million stock awards granted for the three- and nine-month periods ended September 30, 2020.

At September 30, 2021, there was \$79.8 million remaining in unrecognized compensation expense, less estimated forfeitures, related to these awards which will be recognized over a weighted-average period of 1.98 years.

### Share-Based Compensation Expense

For the three- and nine-month periods ended September 30, 2021 and 2020 was as follows:

(in thousands)	Three months ended September 30,	
	2021	2020
Cost of sales	\$ 1,044	\$ 1,434
Research and development	1,916	2,694
Sales and marketing	3,680	5,717
General and administrative	5,484	4,872
Share-based compensation expense before taxes	12,124	14,717
Less: income tax benefit	2,852	3,609
Net share-based compensation expense	\$ 9,272	\$ 11,108

  

(in thousands)	Nine months ended September 30,	
	2021	2020
Cost of sales	\$ 2,391	\$ 2,676
Research and development	3,563	5,395
Sales and marketing	10,535	11,769
General and administrative	14,932	11,381
Share-based compensation expense before taxes	31,421	31,221
Less: income tax benefit	7,236	7,190
Net share-based compensation expense	\$ 24,185	\$ 24,031

No compensation cost was capitalized at September 30, 2021 or September 30, 2020 as the amounts were not material.

## OPERATING AND FINANCIAL REVIEW AND PROSPECTS

This section contains a number of forward-looking statements. These statements are based on current management expectations, and actual results may differ materially. Among the factors that could cause actual results to differ from management's expectations are those described in "Risk Factors" and "Forward-looking and Cautionary Statements" below.

### Forward-looking and Cautionary Statements

This report contains forward-looking statements that are subject to risks and uncertainties. These statements can be identified by the use of forward-looking terminology, such as "believe," "hope," "plan," "intend," "seek," "may," "will," "could," "should," "would," "expect," "anticipate," "estimate," "continue" or other similar words. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. We caution investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such

forward-looking statements as a result of various factors, including, but not limited to, the following: risks associated with our expansion of operations, including the acquisition of new businesses; variability in our operating results from quarter to quarter; management of growth, international operations, and dependence on key personnel; intense competition; technological change; our ability to develop and protect proprietary products and technologies and to enter into and maintain collaborative commercial relationships; our future capital requirements; general economic conditions and capital market fluctuations; and uncertainties as to the extent of future government regulation of our business. As a result, our future success involves a high degree of risk. For further information, refer to the more specific risks and uncertainties discussed in Part 1, Item 3 "Key Information" of our Annual Report on Form 20-F for the year ended December 31, 2020 and under the heading "Risk Factors" below.

## Results of Operations

### Overview

We are a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis, such as identifying the DNA of a virus or a mutation of a gene. QIAGEN Digital insights integrate software and cloud-based resources to interpret increasing volumes of biological data and report relevant, actionable insights. Our automation solutions tie these together in seamless and cost-effective molecular testing workflows.

We sell our products - consumables, automated instrumentation systems using those technologies, and bioinformatics to analyze and interpret the data - to two major customer classes:

- **Molecular Diagnostics** - healthcare providers engaged in many aspects of patient care requiring accurate diagnosis and insights to guide treatment decisions in oncology, infectious diseases and immune monitoring. Includes Precision Medicine and companion diagnostics.
- **Life Sciences** - customers including government, biotechnology companies and researchers who utilize molecular testing and technologies who are generally served by public funding including areas such as medicine and clinical development efforts, forensics and exploring the secrets of life. Includes Pharma, Academia and Applied Testing customers.

We market products in more than 130 countries, mainly through subsidiaries in markets we believe have the greatest sales potential in Europe, Asia, the Americas and Australia. We also work with specialized independent distributors and importers. As of September 30, 2021, we employed more than 6,000 people in more than 35 locations worldwide.

We expect continued strong demand in the non-COVID product group areas of the portfolio during 2021 and for these products to represent the majority of our sales. The success of vaccination campaigns has led to a reduction in demand for COVID-19 test solutions, and this has led to reduced sales growth over 2020 from these product groups. Investments are planned for research and development and clinical trials to strengthen our five pillars of growth beyond the pandemic, in particular initiatives to enlarge the test menu for the NeuMoDx and QIAstat-Dx systems.

### Three- and Nine-Month Periods Ended September 30, 2021 compared to Three- and Nine-Month Periods Ended September 30, 2020

#### Net Sales

(in millions)	Third quarter			First nine months		
	2021	2020		2021	2020	
	Net sales	Net sales	% change	Net sales	Net sales	% change
<b>Non-COVID and COVID-19 product groups</b>						
Non-COVID product groups	\$ 375.9	\$ 319.7	+18%	\$ 1,147.6	\$ 881.5	+30%
COVID-19 product groups	158.8	164.1	-3%	521.7	417.6	+25%
Net Sales	\$ 534.7	\$ 483.8	+11%	\$ 1,669.3	\$ 1,299.1	+28%
<b>Product type</b>						
Consumables and related revenues	\$ 472.8	\$ 419.9	+13%	\$ 1,469.1	\$ 1,121.3	+31%
Instruments	61.9	63.8	-3%	200.2	177.8	+13%
Net Sales	\$ 534.7	\$ 483.8	+11%	\$ 1,669.3	\$ 1,299.1	+28%

Customer class						
Molecular Diagnostics	\$ 279.2	\$ 237.2	+18%	\$ 830.2	\$ 617.1	+35%
Life Sciences	255.6	246.6	+4%	839.1	682.0	+23%
Net Sales	\$ 534.7	\$ 483.8	+11%	\$ 1,669.3	\$ 1,299.1	+28%

Sales in non-COVID product groups remained strong with growth led by QuantiFERON-TB, Sample technologies and Genomics / NGS products during the third quarter of 2021. Lower COVID-19 product group sales levels in the third quarter of 2021 were driven by a decline in manual RNA extraction sales particularly in the United States. Sales for COVID-19 testing solutions in other regions were strong especially for QIAprep& solutions in the European Union during the third quarter of 2021. Net sales were positively impacted by about one percentage point from favorable currency movements against the U.S. dollar in the third quarter and about three percentage points in the first nine months of 2021.

(in millions)	Third quarter			First nine months		
	2021	2020		2021	2020	
	Net sales	Net sales	% change	Net sales	Net sales	% change
Sample technologies	\$ 202.5	\$ 213.9	-5%	\$ 632.2	\$ 568.1	+11%
Diagnostic solutions	162.2	118.8	+37%	466.1	302.0	+54%
PCR / Nucleic acid amplification	98.5	95.9	+3%	323.9	255.2	+27%
Genomics / NGS	53.0	36.8	+44%	182.9	115.7	+58%
Other	18.6	18.4	+1%	64.1	58.1	+10%
Net Sales	\$ 534.7	\$ 483.8	+11%	\$ 1,669.3	\$ 1,299.1	+28%

Sample technologies represent products, including both COVID-19 and non-COVID products, involved in the first step in any molecular lab process. In the third quarter of 2021, sales of non-COVID products grew 7% and represented 64% of this product group on increased demand for products such as DNA extraction kits. For the first nine months of 2021, non-COVID products rose 22% and represented 64% of this product group. Sales of kits used for COVID-19 testing declined 21% against strong sales for manual RNA extraction kits sold at the height of demand for COVID-19 testing in the third quarter of 2020. COVID-19 related sales in this product group declined 4% during the first nine months of 2021 compared to the year-ago period.

Diagnostic solutions include molecular testing platforms and products as well as Precision Medicine and companion diagnostic co-development revenues. Growth in the third quarter and first nine months of 2021 reflects sales of QIAstat-Dx which rose amid continued demand for syndromic respiratory testing. NeuMoDx sales growth also benefited from COVID-19 demand as well as the increasing use of multiplex testing solutions for ILI (Influenza Like Illnesses) particularly during the third quarter of 2021. Sales in the third quarter and first nine months of 2021 also reflected strong growth in QuantiFERON latent TB sales in all regions. Higher revenues from companion diagnostic co-development agreements compared to the prior year periods were also supported by higher sales of kits used for precision medicine applications.

PCR / Nucleic acid amplification involves research and applied PCR solutions and components. OEM solutions and enzymes used in third-party diagnostic kits contributed to growth in the third quarter and first nine months of 2021. QIAcuity digital PCR sales continued growth trends from the first half of the year amid increasing customer interest and awareness following the launch in late 2020. Higher consumable sales more than outweighed a decline in instrument sales against high pandemic demand in the third quarter of 2020.

Genomics / NGS includes universal NGS solutions as well as the full QIAGEN Digital Insights portfolio. Sales for universal consumables used in next-generation sequencing (NGS) for both Life Sciences and Molecular Diagnostic applications grew during the third quarter and first nine months of 2021. Sales were also driven by QIAGEN Digital Insights in particular in clinical applications during both the third quarter and first nine months of 2021.

(in millions)	Third quarter			First nine months		
	2021	2020		2021	2020	
	Net sales	Net sales	% change	Net sales	Net sales	% change
Americas	\$ 247.9	\$ 227.3	+9%	\$ 748.9	\$ 578.4	+29%
Europe, Middle East and Africa	174.3	164.1	+6%	594.9	457.0	+30%
Asia Pacific, Japan and Rest of World	112.5	92.3	+22%	325.5	263.7	+23%
Net Sales	\$ 534.7	\$ 483.8	+11%	\$ 1,669.3	\$ 1,299.1	+28%



Growth in the Americas region was due to a strong performance in the U.S. which experienced 19% growth including gains in QuantiFERON-TB sales as well as more than 30% growth in the PCR / Nucleic acid amplification and Genomics / NGS product groups during the third quarter. U.S. growth in the Americas region was partially offset by a decline in sales in Brazil during the third quarter and first nine months of 2021 driven by lower sales in Molecular Diagnostics. Mexico declined across both customer classes during the third quarter, however a strong first quarter performance in Mexico resulted in growth in this country for the first nine months of 2021.

Performance in the Europe, Middle East and Africa region was driven by gains in the Diagnostic solutions product group in Italy and Switzerland as well as the PCR / Nucleic acid amplification product group in the United Kingdom during the third quarter and first nine months of 2021. This was balanced against weaker PCR / Nucleic acid amplification sales in France and Sample technologies results in Germany in the third quarter and first nine months compared to the year ago period. EMEA sales were impacted by less than one percentage point from favorable currency movements against the U.S. dollar in the three months ended September 30, 2021 and six percentage points in the nine-month period then ended.

Results in the Asia Pacific, Japan and Rest of World region during the third quarter and first nine months of 2021 were driven by growth in China compared to 2020 on improving trends in instruments and consumables amid improving trends for non-COVID product groups. Higher sales were also seen in Japan, Australia and South Korea, more than absorbing the decline in India compared to the prior year periods. Sales in the Asia Pacific and Japan region were positively impacted by two percentage points from favorable currency movements against the U.S. dollar in the three months ended September 30, 2021 and five percentage points in the nine-month period then ended.

### Gross Profit

(in millions)	Third quarter			First nine months		
	2021	2020	% change	2021	2020	% change
Gross Profit	\$ 337.2	\$ 320.8	+5%	\$ 1,077.0	\$ 859.3	+25%
Gross Margin	63.1 %	66.3 %		64.5 %	66.1 %	

Generally, our consumables and related products have a higher gross margin than our instrumentation products and service arrangements and fluctuations in the sales levels of these products and services can result in fluctuations in gross margin between periods. While net sales from consumables and instruments have shifted towards a higher percentage of consumable sales in both the three- and nine-month periods ended September 30, 2021, the gross margin reflects the impact of third quarter inventory markdowns totaling \$6.2 million for COVID-19 antigen tests.

In the third quarter of 2021, the amortization expense on acquisition-related intangibles within cost of sales increased to \$16.3 million compared to \$15.7 million in the same period of 2020. In the first nine months of 2021, the amortization expense on acquisition-related intangibles within cost of sales increased to \$51.7 million compared to \$45.7 million in the same period of 2020. This increase reflects the acquired intangibles from NeuMoDx as discussed further in Note 3 "Acquisitions" partially offset by the full amortization during 2020 of assets previously acquired in 2007. Our acquisition-related intangible amortization will increase in the event of future acquisitions.

### Operating Expenses

#### Research and Development

(in millions)	Third quarter			First nine months		
	2021	2020	% change	2021	2020	% change
Research and development	\$ 48.3	\$ 36.1	+34%	\$ 147.9	\$ 102.7	+44%
% of net sales	9.0 %	7.5 %		8.9 %	7.9 %	

Research and development costs in the three and nine months ended September 30, 2021 include \$0.6 million and \$6.7 million, respectively, of unfavorable currency exchange impact. The overall increase in research and development expense is the result of the continued focus on our five pillars of growth, including investments in NeuMoDx, QIAstat-Dx and QIAcuity. These investments are being made to expand the use of key solutions within our five pillars of growth as well as to address the ongoing COVID-19 testing demand including the ability to detect emerging viral variants. In 2020, research and development costs reflect the suspended development of NGS-related instrument systems in connection with the 2019 restructuring measures discussed in Note 4 "Restructuring and Impairments". As we continue to discover, develop and acquire new products and technologies, we expect to incur additional expenses related to facilities, licenses and employees engaged in research and development. Overall, research and development costs are expected to increase as a result of seeking regulatory approvals, including U.S. FDA Pre-Market Approval (PMA), U.S. FDA 510(k) clearance and EU CE approval of certain assays or instruments. Further, business combinations, along with the

acquisition of new technologies, may increase our research and development costs in the future. We have a strong commitment to innovation and expect to continue to make investments in our research and development efforts.

### **Sales and Marketing**

(in millions)	Third quarter			First nine months		
	2021	2020	% change	2021	2020	% change
Sales and marketing	\$ 112.9	\$ 102.2	+10%	\$ 337.0	\$ 292.3	+15%
% of net sales	21.1 %	21.1 %		20.2 %	22.5 %	

Sales and marketing expenses are primarily associated with personnel, commissions, advertising, trade shows, publications, freight and logistics expenses, and other promotional expenses. The increase reflects additional sales and marketing efforts supporting our focus on the five pillars of growth, as well as increases in freight and other supply chain costs in line with the increase in sales and includes unfavorable currency exchange impacts of \$0.8 million and \$10.9 million in the three and nine months ended September 30, 2021, respectively. As pandemic restrictions are lifted, we anticipate that absolute sales and marketing costs will increase, along with increases related to new product introductions.

### **General and Administrative**

(in millions)	Third quarter			First nine months		
	2021	2020	% change	2021	2020	% change
General and administrative	\$ 30.4	\$ 27.9	+9%	\$ 95.2	\$ 80.0	+19%
% of net sales	5.7 %	5.8 %		5.7 %	6.2 %	

General and administrative expenses reflect continued investments in information technology systems, including cyber security, across the organization. General and administrative expenses include unfavorable currency exchange impacts of \$0.1 million and \$2.5 million in the three and nine months ended September 30, 2021, respectively. As pandemic restrictions are lifted, we anticipate that absolute general and administrative expense will increase.

### **Acquisition-Related Intangible Amortization**

(in millions)	Third quarter			First nine months		
	2021	2020	% change	2021	2020	% change
Acquisition-related intangible amortization	\$ 4.5	\$ 5.3	-15%	\$ 15.2	\$ 15.4	-1%
% of net sales	0.8 %	1.1 %		0.9 %	1.2 %	

Amortization expense related to developed technology and patent and license rights acquired in a business combination is included in cost of sales. Amortization of trademarks and customer base acquired in a business combination is recorded in operating expense under the caption "acquisition-related intangible amortization." Amortization expenses of intangible assets not acquired in a business combination are recorded within cost of sales, research and development, or sales and marketing based on the use of the asset. Our acquisition-related intangible amortization recorded in operating expenses will increase in the event of future acquisitions.

### **Restructuring, Acquisition, Integration and Other, net**

(in millions)	Third quarter			First nine months		
	2021	2020	% change	2021	2020	% change
Restructuring, acquisition, integration and other, net	\$ 9.4	\$ 104.8	-91%	\$ 24.8	\$ 137.3	-82%
% of net sales	1.8 %	21.7 %		1.5 %	10.6 %	

Restructuring, acquisition, integration and other, net expenses totaled \$9.4 million and \$24.8 million, respectively, during the three and nine months ended September 30, 2021 including costs for the continued integration of NeuMoDx as well as the expense for the \$4.7 million jury awarded damages to ArcherDX.

During the three and nine months ended September 30, 2020, we incurred acquisition expenses of \$103.6 million and \$124.5 million, respectively, associated with the public takeover offer for QIAGEN as well as \$0.3 million and \$1.6 million, respectively, of charges in connection with the 2019 restructuring measures.

### **Long-lived Asset Impairments**

Impairments to intangible assets and property, plant and equipment during the nine months ended September 30, 2020 totaled \$1.0 million and were incurred in connection with the 2019 restructuring measures as further discussed in Note 4 "Restructuring and Impairments".

*Other Expense, net*

(in millions)	Third quarter			First nine months		
	2021	2020	% change	2021	2020	% change
Interest income	\$ 3.3	\$ 1.7	+90%	\$ 7.0	\$ 8.4	-17%
Interest expense	(14.6)	(18.1)	-19%	(42.0)	(54.4)	-23%
Other income (expense), net	30.9	(0.3)		38.6	(1.5)	
Total other expense, net	\$ 19.6	\$ (16.6)	-218%	\$ 3.5	\$ (47.5)	-107%

Interest income includes interest earned on cash, cash equivalents and short-term investments, income related to certain interest rate derivatives as discussed in Note 8 "Derivatives and Hedging" and other components including the interest portion of operating lease transactions. The fluctuations in 2021 compared to the prior year is partially attributable to the duration and level of short-term investments held during the period.

Interest expense primarily relates to debt, discussed in Note 7 "Debt" in the accompanying notes to the condensed consolidated financial statements. The decrease in 2021 is driven by the repayment of the majority of the 2021 Notes after the first quarter of 2020.

For the three-month period ended September 30, 2021, other income, net includes a \$30.2 million gain on the receipt and sale of Invitae shares as discussed further in Note 5 "Investments", \$2.5 million income from equity method investments as well as gains, net from the sale of equity method investments and other investments held in publicly traded companies, partially offset by a \$1.5 million loss on foreign currency transactions.

For the nine-month period ended September 30, 2021, other income, net includes a \$35.8 million gain recognized from the receipt and sale of the Invitae shares and related hedge, \$7.0 million of income from equity method investments, \$0.7 million in income, net from the changes in fair value and sale of investments held in other publicly traded companies, a \$0.3 million gain from the sale of an equity method investment, partially offset by a \$5.9 million loss on foreign currency transactions.

For the three-month period ended September 30, 2020, other expense, net includes \$3.4 million of net losses on foreign currency transactions mostly offset by \$3.1 million of other income which includes \$1.2 million of equity method income as discussed further in Note 5 "Investments" as well as a total of \$1.6 million in gains related to prior sales of assets.

For the nine-month period ended September 30, 2020, other expense, net includes \$5.9 million of net losses on foreign currency transactions as well as the \$2.3 million loss from the sale of an investment in equity securities discussed further in Note 5. These losses were partially offset by \$3.8 million of equity method income and \$1.6 million in gains related to prior sales of assets as well as \$1.0 million gain recognized due to early conversions of the 2021 Cash Convertible Notes.

*Provision for Income Taxes*

(in millions)	Third quarter			First nine months		
	2021	2020	% change	2021	2020	% change
Income before income taxes	\$ 151.5	\$ 27.9	+443%	\$ 460.5	\$ 183.0	+152%
Income tax expense	18.3	11.0	+67%	77.0	36.5	+111%
Net income	\$ 133.1	\$ 16.9		\$ 383.4	\$ 146.5	
Effective tax rate	12.1 %	39.4 %		16.7 %	19.9 %	

Our effective tax rate differs from the Netherlands statutory tax rate of 25% due in part to our operating subsidiaries being exposed to statutory tax rates ranging from zero to 35%. Fluctuations in the distribution of pre-tax (loss) income among our operating subsidiaries can lead to fluctuations of the effective tax rate in the consolidated financial statements. In the third quarters of 2021 and 2020, our effective tax rates were 12.1% and 39.4%, respectively. In the nine months ended September 30, 2021 and 2020, our effective tax rates were 16.7% and 19.9%, respectively. We record partial tax exemptions on foreign income primarily derived from operations in Germany, the Netherlands and Singapore. These foreign tax benefits are due to a combination of favorable tax laws, rules, rulings, and exemptions in these jurisdictions, including intercompany foreign royalty income in Germany which is statutorily exempt from trade tax. Further, we have intercompany financing arrangements in which the intercompany income is nontaxable in Dubai.

In future periods, our effective tax rate may fluctuate from similar or other factors as discussed in “Changes in tax laws or their application and the termination or reduction of certain government incentives, could adversely impact our overall effective tax rate, results of operations or financial flexibility” in Item 3 Risk Factors of the Annual Report on Form 20-F for the year ended December 31, 2020.

### **Liquidity and Capital Resources**

To date, we have funded our business primarily through internally generated funds, debt and private and public sales of equity. Our primary use of cash has been to support continuing operations and our investing activities, including capital expenditure requirements and acquisitions. As of September 30, 2021, we had cash and cash equivalents of \$617.5 million and short-term investments of \$339.8 million. As of December 31, 2020, we had cash and cash equivalents of \$598.0 million and short-term investments of \$117.2 million. Cash and cash equivalents are primarily held in U.S. dollars and euros, other than those cash balances maintained in the local currency of subsidiaries to meet local working capital needs. At September 30, 2021, cash and cash equivalents had increased by \$19.6 million from December 31, 2020, primarily as a result of cash provided by operating activities of \$440.5 million, partially offset by cash used in investing activities of \$297.7 million and cash used in financing activities of \$119.4 million. As of September 30, 2021 and December 31, 2020, we had working capital of \$0.96 billion and \$1.05 billion, respectively.

#### **Cash Flow Summary**

(in millions)	First nine months	
	2021	2020
Net cash provided by operating activities	\$ 440.5	\$ 188.1
Net cash used in investing activities	\$ (297.7)	\$ (388.8)
Net cash (used in) provided by financing activities	\$ (119.4)	\$ 42.8
Effect of exchange rate changes on cash, cash equivalents and restricted cash	\$ (3.9)	\$ (2.2)
Net increase (decrease) in cash, cash equivalents and restricted cash	\$ 19.6	\$ (160.1)

#### **Operating Activities**

For the nine months ended September 30, 2021 and September 30, 2020, we generated net cash from operating activities of \$440.5 million and \$188.1 million, respectively. The net increase in net cash from operating activities is primarily the result of an increase in net income and adjustments for non-cash items. While net income was \$383.4 million for the nine months ended September 30, 2021, non-cash components in income included \$163.8 million of depreciation and amortization, \$31.4 million of share-based compensation expense, and \$24.1 million of amortization of debt discount. Operating cash flows include a net decrease in operating assets and liabilities primarily due to increased inventories to meet the increase in demand and decreased accrued and other liabilities and accounts payable during the first nine months of 2021. Because we rely heavily on cash generated from operating activities to fund our business, a decrease in demand for our products, longer collection cycles or significant technological advances of competitors would have a negative impact on our liquidity.

#### **Investing Activities**

Approximately \$297.7 million of cash was used in investing activities during the nine months ended September 30, 2021 compared to \$388.8 million for the same period in 2020. Cash used in investing activities includes \$362.7 million in purchases of short-term investments, \$138.2 million paid for purchases of property, plant and equipment and \$14.4 million for the purchases of intangible assets partially offset by \$172.2 million from the sale of short term investments, primarily the Invitae shares, and \$47.4 million received for collateral assets. Cash used in investing activities during the nine months ended September 30, 2020 includes \$239.6 million cash paid for acquisitions, net of cash acquired, primarily associated with the acquisition of NeuMoDx, \$150.9 million paid for intangible assets, of which \$119.3 million related to the asset acquisition from Formulatrix, \$86.7 million purchases of property, plant or equipment and \$49.8 million in purchases of short-term investments partially offset by \$144.6 million from proceeds from redemption of short-term investments.

#### **Financing Activities**

Net cash used in financing activities totaled \$119.4 million for the nine months ended September 30, 2021, includes \$83.8 million for repurchases of QIAGEN shares, repayments of long-term debt including \$41.1 million for two tranches of the German Private Placement (Schuldschein) that matured and \$0.2 million for the remaining 2021 Notes, as well as \$21.4 million paid in connection with net share settlement for tax withholding related to the vesting of stock awards, partially offset by \$19.6 million of cash received for collateral liabilities. Cash provided by financing activities for the nine months ended September 30, 2020 includes \$59.3 million of proceeds from short-term debt, \$15.1 million of cash received from collateral assets and \$12.3 million proceeds from the exercise of call options related to the Cash Convertible notes

partially offset by \$34.4 million of payments upon early conversion of a portion of the 2021 Notes and \$13.4 million paid in connection with net share settlement for tax withholding related to the vesting of stock awards.

#### *Other Factors Affecting Liquidity and Capital Resources*

As of September 30, 2021, we carry a total of \$1.9 billion of long-term debt, of which \$371.6 million is current and \$1.6 billion is long-term.

In December 2020, we issued \$500.0 million aggregate principal amount of zero coupon Convertible Notes due in 2027 (2027 Notes). The 2027 Notes will mature on December 17, 2027 unless converted in accordance with their terms prior to such date as described more fully in Note 7 "Debt".

In November 2018, we issued \$500.0 million aggregate principal amount of Cash Convertible Senior Notes which are due in 2024 (2024 Notes). Interest on the 2024 Notes is payable semiannually in arrears at a rate of 1.000% per annum. The 2024 Notes will mature on November 13, 2024 unless repurchased or converted in accordance with their terms prior to such date.

In September 2017, we issued \$400.0 million aggregate principal amount of Cash Convertible Senior Notes which are due in 2023 (2023 Notes). Interest on the 2023 Notes is payable semiannually in arrears at a rate of 0.500% per annum. The 2023 Notes will mature on September 13, 2023 unless repurchased or converted in accordance with their terms prior to such date.

Additionally in 2017, we completed a German private placement consisting of several tranches denominated in either U.S. dollars or Euro at either floating or fixed rates and due at various dates through June 2027. As of September 30, 2021, a total of \$300.1 million is outstanding, of which \$173.4 million is due in October 2022. During the first quarter of 2021, we paid \$41.1 million when two tranches matured as described more fully in Note 7 "Debt".

In March 2014, we issued Cash Convertible Senior Notes of which the remaining \$0.2 million was paid during the three months ended March 31, 2021.

In October 2012, we completed a U.S. private placement with three series at a weighted average interest rate of 3.66%. The following two series remain outstanding at September 30, 2021: (1) \$300 million 10-year term due October 16, 2022 (3.75%); and (2) \$27 million 12-year term due October 16, 2024 (3.90%).

In December 2020, we obtained a €400 million syndicated revolving credit facility with a contractual life of three years with the ability to extend by one year two times. No amounts were utilized at September 30, 2021. The facility can be utilized in Euro and bears interest of 0.550% to 1.500% above EURIBOR, and is offered with interest periods of one, three or six months. The interest rate is linked to our environmental, social and governance (ESG) performance. We have additional credit lines totaling €27 million with no expiration date, none of which were utilized as of September 30, 2021.

In connection with certain acquisitions, we could be required to make additional contingent cash payments totaling up to \$26.6 million based on the achievement of certain revenue and operating results milestones as further discussed in Note 15 "Commitments and Contingencies".

On July 12, 2021, we announced our seventh share repurchase program of up to \$100 million of our common shares. During 2021, we repurchased 1.6 million QIAGEN shares for \$83.8 million (including transaction costs). In October 2021, we repurchased 0.3 million QIAGEN shares for \$16.1 million (including transaction costs). This program has therefore concluded on October 29, 2021. In May 2019, we announced our sixth share repurchase program of up to \$100 million of our common shares. During 2020, we repurchased 1.3 million QIAGEN shares for \$64.0 million (including transaction costs). This program ended in December 2020. Repurchased shares will be held in treasury in order to satisfy various obligations, which include employee share-based remuneration plans.

We expect that cash from financing activities will continue to be impacted by issuances of our common shares in connection with our equity compensation plans and that the market performance of our stock will impact the timing and volume of the issuances. Additionally, we may make future acquisitions or investments requiring cash payments, the issuance of additional equity or debt financing.

We believe that funds from operations, existing cash and cash equivalents, together with the proceeds from any public and private sales of equity, and availability of financing facilities, will be sufficient to fund our planned operations and expansion during the coming year. However, any global economic downturn may have a greater impact on our business than currently expected, and we may experience a decrease in the sales of our products, which could impact our ability to generate cash. If our future cash flows from operations and other capital resources are not adequate to fund our liquidity needs, we may be required to obtain additional debt or equity financing or to reduce or delay our capital expenditures, acquisitions or research and development projects. If we could not obtain financing on a timely basis or at satisfactory terms, or implement timely reductions in our expenditures, our business could be adversely affected.

## **QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Our market risk relates primarily to interest rate exposures on cash, marketable securities, and borrowings and foreign currency exposures on intercompany and third-party transactions. The overall objective of our risk management strategy is to reduce the potential negative earnings effects from changes in interest and foreign currency exchange rates. Exposures are managed through operational methods and financial instruments. We do not use financial instruments for trading or speculative purposes. Our exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from our exposure as discussed in Item 11 of our Annual Report on Form 20-F for the year ended December 31, 2020.

### ***Foreign Currency***

QIAGEN N.V.'s functional currency is the U.S. dollar and most of our subsidiaries' functional currencies are the local currencies of the countries in which they are headquartered. All amounts in the financial statements of entities whose functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows: (1) assets and liabilities at period-end rates, (2) income statement accounts at average exchange rates for the period, and (3) components of shareholders' equity at historical rates. Translation gains or losses are recorded in shareholders' equity, and transaction gains and losses are reflected in net income. Foreign currency transactions in the three- and nine-month periods ended September 30, 2021 resulted in a net loss of \$1.5 million and \$5.9 million, respectively, and \$3.4 million and \$5.9 million in the same periods of 2020 and are included in other income (expense), net.

### ***Derivatives and Hedging***

In the ordinary course of business, we use derivative instruments, including swaps, forwards and/or options, to manage potential losses from foreign currency exposures and variable rate debt. The principal objective of such derivative instruments is to minimize the risks and/or costs associated with global financial and operating activities. We do not utilize derivative or other financial instruments for trading or speculative purposes. We recognize all derivatives as either assets or liabilities on the balance sheet, measure those instruments at fair value and recognize the change in fair value in earnings in the period of change, unless the derivative qualifies as an effective hedge that offsets certain exposures. In determining fair value, we consider both the counterparty credit risk and our own creditworthiness. To determine our own credit risk, we estimated our own credit rating by benchmarking the price of our outstanding debt to publicly-available comparable data from rated companies. Using the estimated rating, we quantify our credit risk by reference to publicly-traded debt with a corresponding rating.

#### ***Foreign Currency Derivatives***

As a globally active enterprise, we are subject to risks associated with fluctuations in foreign currencies in our ordinary operations. This includes foreign currency-denominated receivables, payables, debt, and other balance sheet positions. We manage our balance sheet exposure on a group-wide basis primarily using foreign exchange forward contracts, options and cross-currency swaps.

#### ***Interest Rate Derivatives***

We are using interest rate derivatives to align our portfolio of interest bearing assets and liabilities with our risk management objectives. We have entered into interest rate swaps in which we agreed to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount.

We also make use of economic hedges. Further details of our derivative and hedging activities can be found in Note 8 "Derivatives and Hedging" to the accompanying condensed consolidated financial statements.

## **RECENT AUTHORITATIVE PRONOUNCEMENTS**

For information on recent accounting pronouncements impacting our business, see Note 2 "Basis of Presentation and Accounting Policies" in the accompanying condensed consolidated financial statements.

## **APPLICATION OF CRITICAL ACCOUNTING POLICIES, JUDGMENTS AND ESTIMATES**

The preparation of our financial statements in accordance with accounting principles generally accepted in the United States requires management to make assumptions that affect the reported amounts of assets and liabilities and disclosure of contingencies as of the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that require the most complex or subjective judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. Thus, to the extent that actual events differ from management's estimates and assumptions, there could be a material impact on the financial statements. In applying our critical accounting policies, at times we used accounting estimates that either

required us to make assumptions about matters that were highly uncertain at the time the estimate was made or were reasonably likely to change from period to period, having a material impact on the presentation of our results of operations, financial position or cash flows. While the COVID-19 pandemic presents additional uncertainty, we continue to use the best information available to form our estimates. Our critical accounting policies are those related to revenue recognition, income taxes, investments, goodwill and other intangible assets, acquisitions and fair value measurements.

Our critical accounting policies are discussed further in Item 5 of our Annual Report on Form 20-F for the year ended December 31, 2020. Actual results in these areas could differ from management's estimates.

#### **OFF-BALANCE SHEET ARRANGEMENTS**

We did not use special purpose entities and did not have off-balance-sheet financing arrangements as of September 30, 2021 and December 31, 2020.

#### **CONTRACTUAL OBLIGATIONS**

There were no material changes at September 30, 2021 from the contractual obligations disclosed in Item 5 of our Annual Report on Form 20-F for the year ended December 31, 2020.

#### **LEGAL PROCEEDINGS**

For information on legal proceedings, see Note 15 "Commitments and Contingencies" to the accompanying condensed consolidated financial statements.

While no assurances can be given regarding the outcome of the proceedings described in Note 15, based on information currently available, we believe that the resolution of these matters is unlikely to have a material adverse effect on our financial position or results of future operations for QIAGEN N.V. as a whole. However, because of the nature and inherent uncertainties of litigation, should the outcomes be unfavorable, certain aspects of our business, financial condition, and results of operations and cash flows could be materially adversely affected.

#### **RISK FACTORS**

Material risks that may affect our results of operations and financial position appear in Part 1, Item 3 "Key Information" of the Annual Report on Form 20-F for the year ended December 31, 2020. There have been no material changes from the risk factors disclosed in Item 3 of our Form 20-F.

---